<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7026011</article-id><article-id pub-id-type="doi">10.3389/fmicb.2020.00139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>&#x000c1;lvarez</surname><given-names>Diana M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/636330/overview"/></contrib><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>Estefan&#x000ed;a</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/881565/overview"/></contrib><contrib contrib-type="author"><name><surname>Duarte</surname><given-names>Luisa F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arriagada</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/897695/overview"/></contrib><contrib contrib-type="author"><name><surname>Corrales</surname><given-names>Nicol&#x000e1;s</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/591562/overview"/></contrib><contrib contrib-type="author"><name><surname>Far&#x000ed;as</surname><given-names>M&#x000f3;nica A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/466443/overview"/></contrib><contrib contrib-type="author"><name><surname>Henr&#x000ed;quez</surname><given-names>Adolfo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/897652/overview"/></contrib><contrib contrib-type="author"><name><surname>Agurto-Mu&#x000f1;oz</surname><given-names>Cristian</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/897534/overview"/></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Pablo A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/427054/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Millennium Institute on Immunology and Immunotherapy, Departamento de Gen&#x000e9;tica Molecular y Microbiolog&#x000ed;a, Facultad de Ciencias Biol&#x000f3;gicas, Pontificia Universidad Cat&#x000f3;lica de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff2"><sup>2</sup><institution>Centro de Biotecnolog&#x000ed;a, Universidad de Concepci&#x000f3;n</institution>, <addr-line>Concepci&#x000f3;n</addr-line>, <country>Chile</country></aff><aff id="aff3"><sup>3</sup><institution>Departamento de Ciencia y Tecnolog&#x000ed;a de Alimentos, Facultad de Farmacia, Universidad de Concepci&#x000f3;n</institution>, <addr-line>Concepci&#x000f3;n</addr-line>, <country>Chile</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Michael Nevels, University of St Andrews, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: David Leib, Dartmouth College, United States; Guangdi Li, Central South University, China</p></fn><corresp id="c001">*Correspondence: Pablo A. Gonz&#x000e1;lez, <email>pagonzalez@bio.puc.cl</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><elocation-id>139</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 &#x000c1;lvarez, Castillo, Duarte, Arriagada, Corrales, Far&#x000ed;as, Henr&#x000ed;quez, Agurto-Mu&#x000f1;oz and Gonz&#x000e1;lez.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>&#x000c1;lvarez, Castillo, Duarte, Arriagada, Corrales, Far&#x000ed;as, Henr&#x000ed;quez, Agurto-Mu&#x000f1;oz and Gonz&#x000e1;lez</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are highly prevalent within the human population and are characterized by lifelong infections and sporadic recurrences due to latent neuron infection. Upon reactivations, HSVs may manifest either, symptomatically or asymptomatically and be shed onto others through mucosae body fluids. Although, HSVs can produce severe disease in humans, such as life-threatening encephalitis and blindness, the most common symptoms are skin and mucosal lesions in the oro-facial and the genital areas. Nucleoside analogs with antiviral activity can prevent severe HSV infection, yet they are not very effective for treating skin manifestations produced by these viruses, as they only reduce in a few days at most the duration of lesions. Additionally, HSV variants that are resistant to these antivirals may arise, especially in immunosuppressed individuals. Thus, new antivirals that can reduce the severity and duration of these cutaneous manifestations would certainly be welcome. Here, we review currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses.</p></abstract><kwd-group><kwd>HSV-1</kwd><kwd>HSV-2</kwd><kwd>natural antiviral compounds</kwd><kwd>antiviral extracts</kwd><kwd>phytopharmaceuticals</kwd><kwd>therapy</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100002850</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><equation-count count="0"/><ref-count count="207"/><page-count count="19"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 virus (HSV-2) are viruses belonging to the <italic>Herpesviridae</italic> family, <italic>Alphaherpesvirinae</italic> subfamily and <italic>Simplexvirus</italic> genus. HSV-1 and HSV-2 belong to the same family and subfamily than varicella zoster virus (VZV), yet VZV belongs to the <italic>Varicellovirus</italic> genus (<xref rid="B127" ref-type="bibr">McGeoch, 2009</xref>; <xref rid="B93" ref-type="bibr">Kinchington et al., 2012</xref>; <xref rid="B78" ref-type="bibr">Ib&#x000e1;&#x000f1;ez et al., 2018</xref>). HSV-1 and HSV-2 are highly prevalent in humans, with global infections ranging 70 and 10% of the world population, respectively (<xref rid="B173" ref-type="bibr">Smith and Robinson, 2002</xref>; <xref rid="B165" ref-type="bibr">Schillinger et al., 2004</xref>; <xref rid="B116" ref-type="bibr">Looker et al., 2008</xref>; <xref rid="B28" ref-type="bibr">Chayavichitsilp et al., 2009</xref>; <xref rid="B49" ref-type="bibr">Doi et al., 2009</xref>) (World Health Organization, Regional Estimates<sup><xref ref-type="fn" rid="footnote1">1</xref></sup>.</p><p>HSV-1 and HSV-2 can cause severe disease in immunocompetent adults and newborns, such as life-threatening encephalitis with sequelae, despite antiviral treatment (<xref rid="B197" ref-type="bibr">Whitley et al., 2007</xref>; <xref rid="B204" ref-type="bibr">Xu et al., 2007</xref>; <xref rid="B48" ref-type="bibr">Dinh et al., 2008</xref>; <xref rid="B69" ref-type="bibr">Handel et al., 2011</xref>). These viruses can also produce eye infections leading to visual impairment: currently, HSV-1 is the main cause of infectious blindness in developed countries (<xref rid="B58" ref-type="bibr">Farooq and Shukla, 2012</xref>). However, the most common clinical manifestations associated to HSV-1 and HSV-2 infections are <italic>herpes labialis</italic> and <italic>herpes genitalis</italic> (<xref rid="B99" ref-type="bibr">Lafferty et al., 1987</xref>; <xref rid="B131" ref-type="bibr">Mertz et al., 1998</xref>; <xref rid="B91" ref-type="bibr">Kaye and Choudhary, 2006</xref>; <xref rid="B143" ref-type="bibr">Paz-Bailey et al., 2008</xref>; <xref rid="B58" ref-type="bibr">Farooq and Shukla, 2012</xref>), which are characterized by the appearance of vesicular ulcers in the oro-facial and genital areas that gradually dry out into crusts and may last up to 14 days during primary infections and approximately 10 days during recurrences if no treatment is undertaken (<xref rid="B7" ref-type="bibr">Arduino and Porter, 2007</xref>). Lesion development is sequential and begins with a prodrome displaying erythema, then papules emerge which may progress into vesicles that break up giving way to the formation of ulcers. Finally, these ulcers dry out forming scabs, which are accompanied by residual swelling and finally healing (<xref rid="B178" ref-type="bibr">Spruance et al., 1977</xref>; <xref rid="B38" ref-type="bibr">Corey et al., 1983</xref>; <xref rid="B59" ref-type="bibr">Fatahzadeh and Schwartz, 2007</xref>). The lesions contain high amounts of virions and infiltrating leukocytes and may be painful with a burning sensation, ultimately impacting the quality of life of the affected individuals (<xref rid="B178" ref-type="bibr">Spruance et al., 1977</xref>; <xref rid="B50" ref-type="bibr">Dreno et al., 2012</xref>).</p><p>Nevertheless, not all the individuals infected with HSV-1 and HSV-2 manifest symptoms. It is estimated that herpetic recurrences due to HSV occur within a wide range of frequencies, varying between 20&#x02013;50% and 80&#x02013;90% for HSV-1 and HSV-2 infections, respectively after primary infection (<xref rid="B130" ref-type="bibr">Mertz et al., 1992</xref>; <xref rid="B15" ref-type="bibr">Benedetti et al., 1994</xref>; <xref rid="B39" ref-type="bibr">Cowan et al., 1994</xref>; <xref rid="B61" ref-type="bibr">Fleming et al., 1997</xref>). This means that 50&#x02013;80% and 10&#x02013;20% of individuals with HSV-1 and HSV-2 infection, correspondingly will not show clinical symptoms of infection. Yet, it is important to note that these persons will nevertheless shed infectious viral particles from the mucosae, which could infect other individuals (<xref rid="B85" ref-type="bibr">Johnston and Corey, 2015</xref>; <xref rid="B152" ref-type="bibr">Ramchandani et al., 2017</xref>). On the other hand, up to one-third of the persons that have had clinical symptoms during primary infection show frequent reactivations, which occur on average six times a year (<xref rid="B15" ref-type="bibr">Benedetti et al., 1994</xref>). Overall, it is currently estimated that 10&#x02013;25% of the individuals that are infected with HSV manifest disease symptoms, particularly skin lesions in various forms (<italic>herpes labialis</italic>, <italic>herpes genitalis</italic>, <italic>eczema herpeticum, zosteriforme</italic> herpes, etc.) (<xref rid="B130" ref-type="bibr">Mertz et al., 1992</xref>; <xref rid="B39" ref-type="bibr">Cowan et al., 1994</xref>; <xref rid="B61" ref-type="bibr">Fleming et al., 1997</xref>). Taking into consideration the numbers outlined above, approximately 16 and 5% of the world population will manifest herpetic lesions with HSV-1 and HSV-2, respectively. This extremely high percentage of individuals affected by symptomatic HSV infection is non-negligible and undoubtedly encompasses a significant number of persons that would like to have access to more effective solutions against these viruses.</p><p>The reactivation of HSV-1 and HSV-2 from infected individuals is associated with numerous factors, such as immune-related and physicochemical stimuli, such as UV radiation, as well as menstruation, stress and traumatic events, among others (<xref rid="B144" ref-type="bibr">Perna et al., 1987</xref>; <xref rid="B153" ref-type="bibr">Rand et al., 1990</xref>). Upon viral reactivation, virions travel in a retrograde manner from the cell body of infected neurons in the trigeminal ganglia (orofacial infection), or the dorsal root ganglia (genital-associated infection), to sites neighboring epithelial cells and fibroblasts, nearby the original site of infection, forming new lesions that will repeat the process of additional neuron infection (<xref rid="B180" ref-type="bibr">Stevens and Cook, 1971</xref>; <xref rid="B99" ref-type="bibr">Lafferty et al., 1987</xref>; <xref rid="B15" ref-type="bibr">Benedetti et al., 1994</xref>). Given this scenario, it seems important to block neuron infection by HSV-1 and HSV-2 during primary infection or to treat neurons in such a way that these viruses do not reactivate from these cells. However, a prophylactic approach for HSV-1 and HSV-2 is yet not available in the form of a vaccine (<xref rid="B98" ref-type="bibr">Kwant and Rosenthal, 2004</xref>; <xref rid="B14" ref-type="bibr">Belshe et al., 2012</xref>) and the effective eradication of these viruses from neurons requires further research (<xref rid="B191" ref-type="bibr">van Diemen et al., 2016</xref>; <xref rid="B192" ref-type="bibr">van Diemen and Lebbink, 2017</xref>; <xref rid="B32" ref-type="bibr">Chen et al., 2018</xref>).</p><p>At present, there are several commercially available antivirals to treat skin lesions caused by HSV-1 and HSV-2. However, such drugs are somewhat ineffective for this type of clinical manifestation, as they only shorten the recovery time of the lesions in 1&#x02013;2 days in most cases (<xref rid="B55" ref-type="bibr">Evans et al., 2000</xref>; <xref rid="B108" ref-type="bibr">Leflore et al., 2000</xref>). For some individuals, the effectiveness of these treatments may be imperceptible [meta-analysis: <xref rid="B29" ref-type="bibr">Chen et al. (2016)</xref>].</p><p>On the other hand, approximately 3.5&#x02013;10% of immunosuppressed individuals (e.g., transplanted persons, HIV-positive individuals, those undergoing pharmacological treatments to depress the immune system, among others) may develop HSV-1 and HSV-2 variants that are resistant to the most commonly used antivirals (<xref rid="B182" ref-type="bibr">Stranska et al., 2005</xref>; <xref rid="B207" ref-type="bibr">Ziyaeyan et al., 2007</xref>; <xref rid="B183" ref-type="bibr">Suazo et al., 2014</xref>; <xref rid="B115" ref-type="bibr">Lolis et al., 2016</xref>). Although second line antivirals exist for these drug-resistant isolates, such as for acyclovir-resistant variants, unfortunately most of these compounds elicit numerous adverse effects (discussed below) (<xref rid="B82" ref-type="bibr">Javaly et al., 1999</xref>). In immunocompetent individuals, drug-resistant variants such as acyclovir-resistant isolates may also occur, yet at a lower frequency (approximately 1% of cases) (<xref rid="B9" ref-type="bibr">Bacon et al., 2002</xref>; <xref rid="B182" ref-type="bibr">Stranska et al., 2005</xref>; <xref rid="B207" ref-type="bibr">Ziyaeyan et al., 2007</xref>). Although this number seems small, considering the significant number of individuals infected with HSV-1 and HSV-2, the figure is substantial.</p><p>Several natural products have shown antiviral effects against HSV-1 and HSV-2, such as extracts, fractionated compounds and isolated molecules originated from marine organisms, microorganisms, fungi, animals, algae and plants, among others (<xref rid="B70" ref-type="bibr">Hassan et al., 2015</xref>). Among these bioactive products there are marine-derived nucleosides, such as spongothymidine and spongouridin, which gave origin to the first nucleoside analog drugs approved to control HSV-1 and HSV-2 infection (<xref rid="B70" ref-type="bibr">Hassan et al., 2015</xref>). Additionally, many plants used in herbal medicine have been reported worldwide to have antiviral effects against HSV-1 and HSV-2 (<xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref>; <xref rid="B80" ref-type="bibr">Jadhav et al., 2012</xref>; <xref rid="B20" ref-type="bibr">Brand et al., 2016</xref>; <xref rid="B112" ref-type="bibr">Li et al., 2018</xref>). Interestingly, different types of natural compounds display antiherpetic activity, such as alkaloids (<xref rid="B176" ref-type="bibr">Souza et al., 2007</xref>), polysaccharides (<xref rid="B41" ref-type="bibr">Damonte et al., 2009</xref>) and proteins (<xref rid="B67" ref-type="bibr">Gu et al., 2007</xref>).</p><p>Here, we review and discuss current antivirals used against HSV-1 and HSV-2, novel antiviral molecules tested in clinical trials against these viruses, as well as new compounds of botanical origin that have emerged in the last 20 years to treat herpes simplex viruses.</p></sec><sec id="S2"><title>Current Drugs Used Against HSV-1 and HSV-2</title><p>At present, there are numerous antiviral drugs for the treatment of HSV infections. Some commonly known anti-herpetic drugs that are currently being used include acyclovir (ACV), penciclovir, and famciclovir, which inhibit HSV-1 and HSV-2 infection by interfering with the viral DNA polymerase and hence, viral genome replication (<xref rid="B96" ref-type="bibr">Kukhanova et al., 2014</xref>). These drugs are also used to treat other herpesvirus infections, such as VZV and cytomegalovirus (human herpesvirus 5, HHV-5, CMV). Although several of these drugs, which are described in more detail below, help reduce disease and minimize potential severe damage, as well as to limit the spread of these viruses onto other individuals, most of these compounds only modestly reduce cutaneous manifestations (lesions) caused by herpes simplex viruses, particularly when used in the form of creams that are applied topically to the skin (<xref rid="B101" ref-type="bibr">Lebrun-Vignes et al., 2007</xref>; <xref rid="B68" ref-type="bibr">Hammer et al., 2018</xref>).</p><sec id="S2.SS1"><title>Acyclovir</title><p>Numerous antivirals approved for the treatment of HSV-1 and HSV-2 infections are acyclic nucleoside and nucleotide analogs that interfere with the elongation of viral genome during replication, which is carried out by the viral DNA polymerase (UL30). Acyclovir (ACV) is an acyclic guanosine analog discovered in the sponge <italic>Cryptotethya crypta</italic> and is at present the most frequently used compound to treat HSV-1 and HSV-2, mainly because of its low price, tolerability and safety (<xref rid="B70" ref-type="bibr">Hassan et al., 2015</xref>). Importantly, acyclovir needs to be activated intracellularly by its phosphorylation into acyclovir triphosphate for exerting its antiviral activity. This process is carried out by the viral thymidine kinase (TK, <italic>UL23</italic> gene), which catalyzes acyclovir into acyclovir monophosphate, thus increasing the concentration of acyclovir within infected cells by reducing its exit from the cell (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>; <xref rid="B96" ref-type="bibr">Kukhanova et al., 2014</xref>). Additional phosphorylations are carried out by cellular kinases and once in its triphosphate form, acyclovir becomes a substrate for the viral DNA polymerase interfering with DNA synthesis (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>; <xref rid="B42" ref-type="bibr">De Clercq, 2013</xref>). Importantly, inhibition of the synthesis of new viral genome copies, which translates lesser formation of novel infectious viral particles, does not affect latent virus within host neurons and hence, does not cure infection (<xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). Other limitations related to the treatment with ACV also exist. For instance, oral intake of ACV has an absorption efficiency of only 15&#x02013;30% (<xref rid="B12" ref-type="bibr">Bean, 1992</xref>), and previous reports indicated that senior patients that had renal problems could experience significant neurotoxicity, because they were not able to properly excrete this drug (<xref rid="B27" ref-type="bibr">Chau, 2018</xref>). Another important limitation associated to ACV is the ability of HSV-1 and HSV-2 to mutate and generate variants that are resistant to this drug by acquiring point mutations in the gene encoding for the viral thymidine kinase (TK), which decreases enzyme expression or modifies substrate specificity abrogating acyclovir phosphorylation, or by acquiring mutations in the gene encoding for the viral DNA polymerase (<italic>UL30</italic>), which may enable HSV-1 and HSV-2 to replicate in the presence of ACV (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>). Such ACV-resistant variants occur mainly in immunosuppressed individuals, as they are otherwise generally attenuated in immunocompetent individuals (<xref rid="B60" ref-type="bibr">Field, 2001</xref>; <xref rid="B135" ref-type="bibr">Morfin and Thouvenot, 2003</xref>).</p><p>Oral intake of ACV for treating skin lesions produced by HSV-1 and HSV-2 only reduces the healing process in little more than 2 days (time to loss of scab), from 7.9 days (placebo group) to 5.8 days, if taken as soon as signs of the prodrome or erythema are detected (<xref rid="B179" ref-type="bibr">Spruance et al., 1990</xref>). Because these differences are moderate, although statistically significant, the clinical benefit of these antiviral drugs for the treatment of herpetic lesions has been somewhat questioned (<xref rid="B95" ref-type="bibr">Kroon, 1990</xref>; <xref rid="B132" ref-type="bibr">Mindel, 1991</xref>). Importantly, when the drug is taken at the stage of papule, a significant effect for ACV is not observed (<xref rid="B177" ref-type="bibr">Spruance, 1993</xref>). Furthermore, within this scenario, the recovery time of cutaneous lesions was found to be larger in the treated group (antiviral) than in the placebo group (8 days vs. 7.2 days, respectively). Regretfully, nearly 50% of patients fail to perceive initial stages of the prodrome and the erythema phases before papule formation and therefore these individuals will not be in time to start an effective oral treatment with ACV in such a way to significantly reduce the time of the herpetic lesions (<xref rid="B179" ref-type="bibr">Spruance et al., 1990</xref>; <xref rid="B177" ref-type="bibr">Spruance, 1993</xref>). Thus, treatment with ACV has poor benefits under these circumstances (<xref rid="B179" ref-type="bibr">Spruance et al., 1990</xref>).</p><p>As an alternative to oral intake, ACV can be applied topically as a cream. Although topical application of ACV over herpetic lesions at the papule stage has beneficial effects, these benefits are relatively weak, since they only reduce healing time in approximately one or two days during <italic>herpes labialis</italic> (<xref rid="B12" ref-type="bibr">Bean, 1992</xref>; <xref rid="B55" ref-type="bibr">Evans et al., 2000</xref>) and three days in genital herpes infections (<xref rid="B187" ref-type="bibr">Thin et al., 1983</xref>; <xref rid="B108" ref-type="bibr">Leflore et al., 2000</xref>).</p></sec><sec id="S2.SS2"><title>Valacyclovir, Penciclovir, and Famciclovir</title><p>Besides ACV, there are other alternatives to treat skin lesions caused by herpes simplex viruses, such as valacyclovir, penciclovir, and famciclovir, which are also considered first-line drugs to treat HSV-1 and HSV-2 and thus, are frequently used (<xref rid="B92" ref-type="bibr">Kimberlin and Whitley, 2007</xref>).</p><p>These drugs are nucleic acid analogs, similar to ACV with a shared mechanism of action that interferes with the function of the viral DNA polymerase (<xref rid="B42" ref-type="bibr">De Clercq, 2013</xref>). These compounds differ from each other mainly in their bioavailability, half-life in the body and dosing (<xref rid="B195" ref-type="bibr">Wagstaff and Bryson, 1994</xref>), yet similar to ACV they reduce herpetic lesions and associated pain in approximately 1&#x02013;3 days, as compared to untreated groups when used topically (<xref rid="B53" ref-type="bibr">Emmert, 2000</xref>).</p><p>To increase the bioavailability of acyclovir, an L-valine ester of acyclovir was developed. Valacyclovir is a prodrug of ACV with enhanced absorption at the intestinal level (54%) (<xref rid="B174" ref-type="bibr">Soul-Lawton et al., 1995</xref>). Later, penciclovir was developed with the aim of being phosphorylated more rapidly than ACV, and consequently has a higher half-life than acyclovir (<xref rid="B73" ref-type="bibr">Hodge and Perkins, 1989</xref>). While acyclovir has a half-life of 0.7 h for HSV-1 and 1 h for HSV-2, penciclovir has a half-life of 10 h for HSV-1 and 20 h for HSV-2 (<xref rid="B118" ref-type="bibr">Luber and Flaherty, 1996</xref>). Famciclovir is a prodrug that derives into penciclovir and has increased oral bioavailability (<xref rid="B74" ref-type="bibr">Hodge et al., 1989</xref>). Clinical benefits granted by these drugs have also generated discussions on the recommendation of their use to treat skin lesions caused by herpes simplex virus infections (<xref rid="B33" ref-type="bibr">Chi et al., 2015</xref>; <xref rid="B29" ref-type="bibr">Chen et al., 2016</xref>).</p><p>Valacyclovir has also been approved for the treatment of HSV-1 and HSV-2 infections and clinical manifestations produced by HSV-1 and HSV-2, such as cold sores and recurrent genital herpes, as well as VZV and cytomegalovirus (<xref rid="B138" ref-type="bibr">Ormrod et al., 2000</xref>). Furthermore, famciclovir is approved for treating herpes viruses, such as HSV-1 and HSV-2 (genital herpes and orolabial herpes), as well as VZV (<xref rid="B171" ref-type="bibr">Simpson and Lyseng-Williamson, 2006</xref>).</p><p>Resistance to valacyclovir, penciclovir, and famciclovir can occur. Furthermore, there is cross-resistance between valacyclovir- and acyclovir-resistant HSV isolates (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>), because valacyclovir is derived from acyclovir (<xref rid="B134" ref-type="bibr">Moomaw et al., 2003</xref>). On the other hand, cross resistance to penciclovir and the prodrug famciclovir may arise in acyclovir-resistant HSV-1 isolates in immunocompromised patients (<xref rid="B19" ref-type="bibr">Boyd et al., 1993</xref>). Some studies have reported HSV-1 and HSV-2 resistance to penciclovir in cell cultures and in immunocompromised patients related to TK-deficiency (<xref rid="B19" ref-type="bibr">Boyd et al., 1993</xref>; <xref rid="B162" ref-type="bibr">Sarisky et al., 2002</xref>, <xref rid="B163" ref-type="bibr">2003</xref>; <xref rid="B10" ref-type="bibr">Bacon et al., 2003</xref>).</p></sec><sec id="S2.SS3"><title>Ganciclovir, Cidofovir and Foscarnet</title><p>In the last decade, alternatives to ACV for herpesvirus treatment have emerged and become commercially available as therapeutic drugs. Ganciclovir is a nucleic acid analog that does not require viral proteins for its activation in the cell (i.e., viral TK) (<xref rid="B122" ref-type="bibr">Markham and Faulds, 1994</xref>; <xref rid="B149" ref-type="bibr">Prichard et al., 2011</xref>; <xref rid="B194" ref-type="bibr">Vere Hodge and Field, 2013</xref>; <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). These compounds differ from each other either, in their molecular processing into an active form of an acyclic guanosine analog, or bioavailability which significantly determines the frequency of administration (<xref rid="B42" ref-type="bibr">De Clercq, 2013</xref>).</p><p>Ganciclovir is indicated for the treatment of CMV, particularly for systemic and ocular infections in immunosuppressed patients (<xref rid="B25" ref-type="bibr">Buhles et al., 1988</xref>; <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). However, ganciclovir has also been reported to have antiviral activity against HSV-1 and HSV-2 and may be used for the treatment of herpetic keratitis (<xref rid="B172" ref-type="bibr">Smee et al., 1983</xref>; <xref rid="B124" ref-type="bibr">Matthews and Boehme, 1988</xref>; <xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>). At present, there is an ongoing clinical study that is recruiting patients for assessing the effects of oral ganciclovir, together with femtosecond laser-assisted corneal debridement in the treatment of herpes simplex virus epithelial keratitis (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT03217474). Of note, ganciclovir has been reported to produce considerable adverse side effects in a high percentage of individuals (<xref rid="B92" ref-type="bibr">Kimberlin and Whitley, 2007</xref>), such as nephrotoxicity, neutropenia, myelosuppression, confusion, altered mental status, anxiety, ataxia, tremors, convulsions, fever, abnormal levels of liver enzymes in serum, diarrhea, and nausea, among others (<xref rid="B92" ref-type="bibr">Kimberlin and Whitley, 2007</xref>).</p><p>Other alternative drugs that have emerged in the last decades as second-line drugs that are commercially available are cidofovir (an acyclic nucleotide analog) (<xref rid="B8" ref-type="bibr">Ashley et al., 1988</xref>; <xref rid="B17" ref-type="bibr">Blot et al., 2000</xref>; <xref rid="B81" ref-type="bibr">James and Prichard, 2014</xref>) and foscarnet (a pyrophosphate analog) (<xref rid="B40" ref-type="bibr">Crumpacker, 1992</xref>; <xref rid="B195" ref-type="bibr">Wagstaff and Bryson, 1994</xref>). When compared to each other, these two compounds affect different steps in the viral replication cycle. Cidofovir acts as a nucleotide analog and polymerase inhibitor with a high affinity for the viral DNA polymerase, with cidofovir-diphosphate having 25&#x02013;50 fold higher affinity for the viral DNA polymerase than the host DNA polymerase, causing thus a more effective block in the replication of viral DNA than acyclovir (<xref rid="B72" ref-type="bibr">Ho et al., 1991</xref>). Importantly, cidofovir has a phosphonate group that does not require an initial phosphorylation step by HSV proteins (<xref rid="B72" ref-type="bibr">Ho et al., 1991</xref>). Cidofovir has shown to be efficacious against acyclovir-resistant isolates of HSV-1 or HSV-2 <italic>in vitro</italic> (<xref rid="B34" ref-type="bibr">Chilukuri and Rosen, 2003</xref>). However, this drug has not been approved for the treatment of herpes simplex viruses in humans. Yet, a clinical study was carried out to evaluate the effectivity of topical cidofovir for refractory mucocutaneous HSV-1 and HSV-2 in AIDS; However, the results of this clinical study have not been reported (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT00002116). On the other hand, foscarnet inhibits the viral DNA polymerase of herpesviruses by binding near to the pyrophosphate binding site that is needed for polymerase activity (<xref rid="B40" ref-type="bibr">Crumpacker, 1992</xref>; <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). In contrast to nucleoside analogs, resistance to foscarnet only occurs because of mutations in the viral DNA polymerase gene (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>).</p><p>Regretfully, these two drugs also produce numerous adverse effects in patients, such as nephrotoxicity, azotemia, proteinuria, crystalluria, interstitial nephritis, acute tubular necrosis, increases in the concentrations of creatinine up to 50%, hypo- and hypercalcemia, hypo- and hyper-phosphatemia, and the formation of urogenital ulcers, among others (<xref rid="B46" ref-type="bibr">Deray et al., 1989</xref>; <xref rid="B164" ref-type="bibr">Sauerbrei, 2016</xref>). Because of these effects, it is recommended that patients receiving foscarnet be monitored clinically to control abnormalities in metabolites and electrolytes that may result in the alterations indicated above.</p><p>Resistance to foscarnet has been observed in immuno- compromised individuals, particularly in patients having undergone bone marrow transplants. On the other hand, there are only few studies reporting cidofovir-resistant HSV isolates. In one case, three patients with bone marrow transplants received cidofovir as a therapy, but nevertheless showed HSV-related diseases symptoms. Cidofovir resistance was confirmed in one of the three cases with the isolate showing mutations that truncated the C-terminal of the viral DNA polymerase (<xref rid="B203" ref-type="bibr">Wyles et al., 2005</xref>). Notably, cidofovir resistance has also been reported in children, particularly in three patients with hematopoietic stem cell transplants that received, in a prophylactic manner acyclovir and cidofovir together, because ganciclovir produced adverse effects. Unfortunately, these children showed HSV-related stomatitis during cidofovir treatment and the authors suggested that the treatment with cidofovir did not prevent HSV-1 reactivation in the patients (<xref rid="B51" ref-type="bibr">Dvorak et al., 2009</xref>). Nevertheless, cidofovir is considered a good option when encountering HSV isolates that express reduced amounts of enzymes that are related to the phosphorylation of nucleoside analogs, or resistance to foscarnet (<xref rid="B155" ref-type="bibr">Reusser, 1996</xref>). For example, <xref rid="B17" ref-type="bibr">Blot et al. (2000)</xref> reported a clinical case of a child affected by a variant of HSV-1 resistant to ACV and foscarnet (<italic>in vitro</italic>), in which case the treatment with cidofovir was effective against this drug-resistant HSV-1. Another study reporting an HSV-1 isolate resistant to both, ACV and foscarnet in a girl with lymphatic leukemia indicated that only cidofovir treatment was successful at helping avoid recurrent oral stomatitis (<xref rid="B23" ref-type="bibr">Bryant et al., 2001</xref>).</p><p>Due to the somewhat reduced clinical benefits of the drugs mentioned above in the treatment of skin lesions caused by herpes simplex viruses, new therapeutic alternatives have emerged in the most recent years. One of these alternatives is a combination of acyclovir and hydrocortisone for topical use (Xerese<sup>&#x000ae;</sup>, Medivir). This formulation reduces the duration of herpetic lesions by 1.6 days (compared to 1.0 days by acyclovir when applied alone as a topic in that study) and reduces the size of the lesion area by 50% (<xref rid="B181" ref-type="bibr">Strand et al., 2012</xref>). While this approach yields a statistically significant improvement in the treatment of herpetic lesions, it still evidences the need for identifying new drugs or drug combinations that have even better effectiveness.</p><p>Another relatively new drug to treat skin lesions caused by HSV-1 is docosanol 10% formulated as a topical cream (Abreva<sup>&#x000ae;</sup>, Avanir), which is the only FDA approved formulation available over the counter (OTC) to treat HSV-1 symptoms. This drug consists of an aliphatic chain (hydrophobic linear chain) with an alcohol group at one of its ends and has emulsifying properties, which is why it has been used in both, the cosmetic and food industries. Currently, docosanol 10% cream is approved for the treatment of HSV-1 lesions. However, the literature available on its effectiveness is somewhat scarce and more studies seem to be required to compare its effectiveness side by side with other compounds such as acyclovir 5% cream and Xerese<sup>&#x000ae;</sup> (<xref rid="B202" ref-type="bibr">Woo and Challacombe, 2007</xref>). One study indicates that docosanol 10% cream reduces the healing time of oral lesions due to HSV-1 and HSV-2 by 18 h (<xref rid="B160" ref-type="bibr">Sacks et al., 2001</xref>). The mechanism of action of docosanol would be mediated by the inhibition of the fusion of the virus to the cell membrane (<xref rid="B147" ref-type="bibr">Pope et al., 1998</xref>).</p><p>On the other hand, another drug marketed to treat skin lesions due to HSV-2 infection is Viroxyn<sup>&#x000ae;</sup> (Quadex Pharmaceuticals), which consists of benzalkonium chloride, a Category III antiseptic, that is also used for various applications, mainly as a biocidal preservative. This compound would act as a virucidal agent over herpes simplex viruses (<xref rid="B13" ref-type="bibr">B&#x000e9;lec et al., 2000</xref>). Although Viroxyn has been sold for more than 16 years, there are only limited studies that have evaluated its effectiveness, some proposing that it is more effective than Abreva<sup>&#x000ae;</sup> (<xref rid="B126" ref-type="bibr">McCarthy et al., 2012</xref>). However, in 2016 the FDA announced a ban on the sale of numerous bactericidal ingredients, leaving benzalkonium chloride in a &#x0201c;stand-by&#x0201d; status until obtaining clinical results that prove its safety in humans, so it may eventually be recalled (&#x0201c;Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use.&#x0201d; 2016-09-06. Retrieved October 05, 2016) (<xref rid="B201" ref-type="bibr">Wolf, 2017</xref>).</p><p>Finally, another compound marketed for treating skin lesions caused by HSV-1 is Novitra<sup>&#x000ae;</sup>, which consists of a zinc oxide-based cream. This compound has been shown to reduce HSV-1 skin lesions by up to 1.5 days, compared to untreated individuals (<xref rid="B66" ref-type="bibr">Godfrey et al., 2001</xref>). Other aspects, such as pain formation and itching, were also shown to be improved with its use. <xref rid="T1" ref-type="table">Table 1</xref> summarizes the antiviral compounds discussed above.</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Approved and experimental antiviral drugs against HSV-1 and HSV-2 (non-botanical).</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Drug</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanism of action</td><td valign="top" align="left" rowspan="1" colspan="1">Type of molecule</td><td valign="top" align="left" rowspan="1" colspan="1">Status</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Acyclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B65" ref-type="bibr">Gnann et al., 1983</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Valacyclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B167" ref-type="bibr">Schuster et al., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Penciclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B128" ref-type="bibr">Meira et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Famciclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B133" ref-type="bibr">Mondal, 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ganciclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Al-Badr and Ajarim, 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Foscarnet</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Pyrophosphate analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B40" ref-type="bibr">Crumpacker, 1992</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cidofovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleotide analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B100" ref-type="bibr">Lea and Bryson, 1996</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Docosanol</td><td valign="top" align="left" rowspan="1" colspan="1">Viral entry inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">Saturated alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B190" ref-type="bibr">Treister and Woo, 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Benzalkonium chloride</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal</td><td valign="top" align="left" rowspan="1" colspan="1">Alkylamine</td><td valign="top" align="left" rowspan="1" colspan="1">Stand-by in the United States</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B186" ref-type="bibr">Taylor-Robinson and Ballard, 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Idoxuridine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Deoxyuridine analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B36" ref-type="bibr">Chou and Hong, 2014; Wilhelmus</xref>, <xref rid="B200" ref-type="bibr">2015</xref>; <xref rid="B44" ref-type="bibr">De Clercq and Li, 2016</xref>; <xref rid="B158" ref-type="bibr">Roozbahani and Hammersmith, 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vidarabine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Trifluridine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by FDA and EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B200" ref-type="bibr">Wilhelmus, 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Brivudine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analog</td><td valign="top" align="left" rowspan="1" colspan="1">Approved by EMA</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B43" ref-type="bibr">De Clercq, 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Brincidofovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleotide analog</td><td valign="top" align="left" rowspan="1" colspan="1">Under FDA Review</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B107" ref-type="bibr">Lee et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amenamevir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Helicase-Primase inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">Being assessed in clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B90" ref-type="bibr">Kawashima et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pritelivir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of viral DNA replication</td><td valign="top" align="left" rowspan="1" colspan="1">Helicase-Primase inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">Being assessed in clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B196" ref-type="bibr">Wald et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nelfinavir mesylate</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits the maturation and export of viral particles</td><td valign="top" align="left" rowspan="1" colspan="1">HIV-1 protease inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">Being assessed in clinical trials for HSV</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B87" ref-type="bibr">Kalu et al., 2014</xref></td></tr></tbody></table></table-wrap></sec><sec id="S2.SS4"><title>Other Anti-HSV Compounds</title><p>Other anti-HSV compounds, are the nucleoside analogs idoxuridine and vidarabine, which are currently discontinued as there are at present better and more effective treatments available. Trifluridine, which is also a nucleoside analogs is mainly used to treat herpetic keratitis.</p><p>Idoxuridine is a thymidine (pyrimidine) analog that was identified as the first effective topical agent against HSV infection (<xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>; <xref rid="B200" ref-type="bibr">Wilhelmus, 2015</xref>), and was mainly used topically as an ointment for treating epithelial keratitis caused by HSV-1 infection of the corneal epithelium (<xref rid="B158" ref-type="bibr">Roozbahani and Hammersmith, 2018</xref>). However, its efficacy was clouded by its toxicity to the corneal epithelium of the eye and poor hydrosolubility and thus, has been currently replaced in favor of more effective, better-tolerated and less-toxic compounds (<xref rid="B200" ref-type="bibr">Wilhelmus, 2015</xref>).</p><p>On the other hand, vidarabine is a purine analog with fewer side-effects than idoxuridine, yet it is also poorly soluble and therefore its use is limited to topical formulations, being less preferable than other current drugs available (<xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>).</p><p>Trifluridine on the other hand is a synthetic pyrimidine nucleoside that is frequently used for the treatment of herpetic keratitis as a topical formulation. This drug was approved by the FDA in 1980 for its use as a 1% solution treatment for HSV-related keratitis and is at present one of the most common used topical antiviral for this type of affection in the United States (<xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>), with considerable effectivity reported (<xref rid="B200" ref-type="bibr">Wilhelmus, 2015</xref>). However, local side effects have been described, some particularly severe. <xref rid="T1" ref-type="table">Table 1</xref> summarizes the antiviral activity of these compounds.</p><p>Finally, another anti-HSV agent is brivudine (BVDU), a pyrimidine analog that acts as a prodrug, phosphorylated by viral thymidine kinase only and thus targeting the viral DNA polymerase (<xref rid="B200" ref-type="bibr">Wilhelmus, 2015</xref>). This compound has been proven to be efficacious against HSV-1 and at least as effective as acyclovir in the treatment of HSV-1 infection (<xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>). Currently, is mainly used in different countries for treatment of VZV infections (<xref rid="B43" ref-type="bibr">De Clercq, 2019</xref>).</p></sec><sec id="S2.SS5"><title>Compounds Against HSVs Currently Being Assessed in Clinical Trials</title><p>Currently, several new anti-herpetic drugs are being assessed in clinical trials, such as brincidofovir (<xref rid="B151" ref-type="bibr">Quenelle et al., 2010</xref>; <xref rid="B149" ref-type="bibr">Prichard et al., 2011</xref>), amenamevir (<xref rid="B35" ref-type="bibr">Chono et al., 2010</xref>), pritelivir (<xref rid="B196" ref-type="bibr">Wald et al., 2014</xref>), and nelfinavir mesylate (<xref rid="B87" ref-type="bibr">Kalu et al., 2014</xref>).</p><p>Brincidofovir is an acyclic nucleotide phosphonate, similar to cidofovir, yet it is conjugated to a lipid (<xref rid="B83" ref-type="bibr">Jiang et al., 2016</xref>). When brincidofovir enters the cell, the lipid sidechain is cleaved and the compound is phosphorylated, acting as a substrate inhibitor for the viral DNA polymerase. Noteworthy, brincidofovir accumulates within the cell significantly more than cidofovir, and has up to 1,000-fold higher antiviral activity as compared to the latter (<xref rid="B75" ref-type="bibr">Hostetler, 2009</xref>). Brincidofovir was evaluated in phase III clinical trial that has concluded, yet to our knowledge the results have not been reported (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT01143181).</p><p>On the other hand, amenamevir and pritelivir target the viral DNA helicase/primase complex (H/P) (<xref rid="B94" ref-type="bibr">Kleymann et al., 2002</xref>; <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). There are three finished clinical studies for pritelivir, yet similar to brincidofovir, the results have not been reported to the best of our knowledge (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT01047540, NCT01658826, and NCT02871492). There is also one clinical study that is currently ongoing and is in the recruitment phase for immunocompromised subjects with acyclovir-resistant mucocutaneous HSV-1 or HSV-2 infection (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT03073967). Amenamevir is an oxadiazolephenyl derivate that belongs to the helicase-primase group of inhibitors and has been evaluated in at least three clinical trials, although the results have not been published (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT02209324, NCT01959295, and NCT02852876) (<xref rid="B35" ref-type="bibr">Chono et al., 2010</xref>). Regretfully, a study indicates that amenamevir displayed adverse events in an early clinical phase against HSV-1 and HSV-2 (<xref rid="B35" ref-type="bibr">Chono et al., 2010</xref>).</p><p>Finally, nelfinavir mesylate, the mesylate salt of the antiviral drug nelfinavir which has been characterized as a HIV-1 protease inhibitor (<xref rid="B142" ref-type="bibr">Patick et al., 1996</xref>; <xref rid="B123" ref-type="bibr">Markowitz et al., 1998</xref>), was found to have antiviral activity against HSV-1 and other herpesviruses and to inhibit the maturation and export of viral particles (<xref rid="B87" ref-type="bibr">Kalu et al., 2014</xref>). As a consequence, nelfinavir mesylate is currently being assessed in a clinical study for the treatment of patients with Kaposi&#x02019;s sarcoma, as well as its potential effectivity activity against HSV-1 and HSV-2, which is a tertiary goal in this study (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT03077451).</p></sec></sec><sec id="S3"><title>Botanical Compounds with Antiviral Activity Against HSVs</title><sec id="S3.SS1"><title>Algae-Derived Compounds With Antiviral Activity Against HSVs in Cell Cultures</title><p>Many studies have reported the existence of algae with bioactive compounds that display potent antiviral activity against numerous viruses, such as dengue (<xref rid="B103" ref-type="bibr">Lee et al., 2006</xref>; <xref rid="B150" ref-type="bibr">Pujol et al., 2012</xref>), avian influenza (<xref rid="B64" ref-type="bibr">Gerber et al., 1958</xref>), HIV (<xref rid="B104" ref-type="bibr">Lee et al., 1999</xref>; <xref rid="B189" ref-type="bibr">Thuy et al., 2015</xref>), human papillomavirus (HPV) (<xref rid="B24" ref-type="bibr">Buck et al., 2006</xref>), and picornavirus (<xref rid="B102" ref-type="bibr">Lee et al., 2009</xref>). Also, numerous studies have reported algae with antiviral activity against herpes simplex viruses (<xref rid="B57" ref-type="bibr">Faral-Tello et al., 2012</xref>; <xref rid="B156" ref-type="bibr">Ribeiro et al., 2012</xref>; <xref rid="B70" ref-type="bibr">Hassan et al., 2015</xref>). A study performed in Brazil analyzed more than 36 species of algae from its coasts and reported that four of them had significant antiviral activity against both, HSV-1 and HSV-2. In their study, the authors suggested that the antiviral activity of extracts of green alga <italic>Stypopodium zonale</italic> (Ochrophyta) against HSV-1 was related to the secondary metabolite atomaric acid (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B156" ref-type="bibr">Ribeiro et al., 2012</xref>). On the other hand, the antiviral activity of <italic>Ulva fasciata</italic> and <italic>Codium decorticatum</italic> against HSV-1 were shown to be mediated by fatty acids present in high concentrations in the extracts, yet the precise molecules involved were not identified or reported (<xref rid="B156" ref-type="bibr">Ribeiro et al., 2012</xref>). For the red alga <italic>Laurencia dendroidea</italic>, the antiviral activity against HSV-1 was likely mediated by sesquiterpenes (<xref rid="B156" ref-type="bibr">Ribeiro et al., 2012</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Structure of botanical molecules with antiviral activity against herpes simplex viruses. Structure of molecules derived from <bold>(A)</bold> algae, <bold>(B)</bold> fungi and <bold>(C)</bold> plants that have been reported to have antiviral activity against HSV-1, HSV-2 or both viruses. Molecular structures were drawn using ACD/ChemSketch<sup>TM</sup>, (version 2018.1.1, Advanced Chemistry Development, Inc., Toronto, ON, Canada, <ext-link ext-link-type="uri" xlink:href="http://www.acdlabs.com">www.acdlabs.com</ext-link>, 2019). Griffithsin (Protein Data Bank accession number <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="2GUD">2GUD</ext-link>) was modeled using PyMOL<sup>TM</sup> (Molecular Graphics System, Version 1.3, Schr&#x000f6;dinger, LLC).</p></caption><graphic xlink:href="fmicb-11-00139-g001"/></fig><p>Another example of an alga with antiviral effects against HSV is <italic>Hypnea musciformis</italic>, a red seaweed present in Italy, which has shown strong antiviral activity against HSV-1, even in different aqueous fractions obtained from its processing. Several mechanisms of action for these preparations were identified, such as virucidal activity and the inhibition of virus binding into the cell (<xref rid="B129" ref-type="bibr">Mendes et al., 2012</xref>). Other reports have also described antiviral effects for different algae extracts against HSVs, such as <italic>Xalas</italic>, a derivative of <italic>Scinaia hatei</italic> that has antiviral activity against HSV-1 and HSV-2, which inhibits the entry of the virus into the cell, and is likely mediated by sulfated xylans present in the extract (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B41" ref-type="bibr">Damonte et al., 2009</xref>). On the other hand, <italic>Osmundaria obtusiloba</italic>, an algae obtained from the Brazilian coast was reported to have antiviral activity against both, HSV-1 and HSV-2, which was suggested to be mediated by algae glycolipids interacting with viral glycoproteins (<xref rid="B175" ref-type="bibr">Souza et al., 2012</xref>). <italic>Padina pavonia</italic>, another algae that inhibits HSV-1 replication, has been reported to have a bioactive compound consisting of sulfated polysaccharides (fucoidan) that hampers the binding of the virus to the surface of the cell (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B71" ref-type="bibr">Hayashi et al., 2008</xref>).</p><p>Extracts derived from the green microalga <italic>Haematococcus pluvialis</italic> have also shown anti-herpetic activity. Extracts obtained from this microalga through pressurized liquid extraction displayed inhibitory action against HSV-1 replication, which was suggested to be mediated by an inhibition in the attachment of the virus to the host cell, the virus-cell fusion process and/or virus entry into the cell (<xref rid="B161" ref-type="bibr">Santoyo et al., 2012</xref>). Another example of an alga extract with antiviral activity against HSV-1 was obtained from <italic>Cystoseira myrica</italic>, which strongly inhibits the replication of this virus (<xref rid="B206" ref-type="bibr">Zandi et al., 2007</xref>).</p><p>Interestingly, researchers have isolated and studied a chemically modified polysaccharide from the green alga <italic>Enteromorpha compressa</italic> with anti HSV-1 activity (<xref ref-type="fig" rid="F1">Figure 1</xref>). Notably, this study reported total viral inhibition when the evaluated compound was added to human Hep-2 cells infected with a clinical isolate of HSV-1 in a time-of-addition assay. Because the effect was maintained when applied post-treatment, the authors suggested that the antiviral activity might be mediated by the inhibition of virus replication and/or viral protein synthesis (<xref rid="B117" ref-type="bibr">Lopes et al., 2017</xref>).</p><p>Another alga which has been studied is <italic>Eucheuma gelatinae</italic>, a red alga that is widespread in tropical and subtropical regions. Polysaccharides obtained from this organism were tested for their antiviral activity against HSV <italic>in vitro</italic> using Vero cells infected with ACV-sensitive or ACV-resistant HSV-1 and HSV-2 isolates (<xref ref-type="fig" rid="F1">Figure 1</xref>). In this study, strong antiviral activity against HSV was observed in early stages of infection affecting the attachment of HSV. Additionally, it was shown experimentally that viral protein synthesis was affected through the evaluation of the expression of the viral protein VP5, as well as the cellular localization of this protein which is normally found in the nucleus. After the treatment with the alga extract, VP5 was mainly found in the cytoplasm (<xref rid="B84" ref-type="bibr">Jin et al., 2015</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Botanical compounds and extracts with antiviral activity against HSV-1 and HSV-2.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Species (common name)</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanism of action</td><td valign="top" align="left" rowspan="1" colspan="1">Virus assessed</td><td valign="top" align="left" rowspan="1" colspan="1">Assessed in cell cultures</td><td valign="top" align="left" rowspan="1" colspan="1">Assessed in animal models</td><td valign="top" align="left" rowspan="1" colspan="1">Active molecule</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Algae</bold></td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Hypnea musciformis</italic> (Hooked Weed)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B129" ref-type="bibr">Mendes et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Stypopodium zonale</italic> (<italic>Ochrophyta</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Atomaric acid</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B156" ref-type="bibr">Ribeiro et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Scinaia hatei</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Xylan (1,4-&#x003b2;-D-xylopyranosyl)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B41" ref-type="bibr">Damonte et al., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Osmundaria obtusiloba</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Interaction with viral glycoproteins</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Sulfoquinovosyldia cylglycerol</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B175" ref-type="bibr">Souza et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Padina pavonica</italic> (Peacock&#x02019;s Tail)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Fucoidan</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B71" ref-type="bibr">Hayashi et al., 2008</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Haematococcus pluvialis</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B161" ref-type="bibr">Santoyo et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Cystoseira myrica</italic> (False Sargassum)</td><td valign="top" align="left" rowspan="1" colspan="1">Viral inhibition before and after absorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B206" ref-type="bibr">Zandi et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Enteromorpha compressa</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral replication, inhibition of viral protein synthesis</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Sulfated polysaccharides</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B117" ref-type="bibr">Lopes et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Eucheuma gelatinae</italic> (Guso)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of viral binding, inhibition of viral gene expression</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Sulfated polysaccharides</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B84" ref-type="bibr">Jin et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Griffithsia</italic> sp. (<italic>Griffiths&#x02019;s Coral Weed</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Griffithsin</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B136" ref-type="bibr">Nixon et al., 2013</xref>; <xref rid="B109" ref-type="bibr">Levendosky et al., 2015</xref>; <xref rid="B47" ref-type="bibr">Derby et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Symphyocladia latiuscula</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B141" ref-type="bibr">Park et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Undaria pinnatifida</italic> (Wakame)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Fucoidan</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B71" ref-type="bibr">Hayashi et al., 2008</xref>; <xref rid="B105" ref-type="bibr">Lee et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Fungi</bold></td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Aspergillus ruber</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Isodihydroauroglaucin Flavoglaucin</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B113" ref-type="bibr">Liang et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Aspergillus versicolor</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Anthraquinones</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B76" ref-type="bibr">Huang et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Scytalidium</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Halovirs A &#x02013; E</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B159" ref-type="bibr">Rowley et al., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Inonotus obliquus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">aqueous extract from <italic>Inonotus obliquus</italic> (AEIO)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Ganoderma lucidum</italic> (Lingzhi Mushroom)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Polysaccharides</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B54" ref-type="bibr">Eo et al., 2000</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Agaricus brasiliensis</italic> (Almond Mushroom)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Polysaccharides</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B26" ref-type="bibr">Cardozo et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Grifola frondosa</italic> (Maltake)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B67" ref-type="bibr">Gu et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Rozites caperata</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Peptides</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Plants</bold></td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Peganum harmala</italic> (Wild Rue)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Harmine</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B16" ref-type="bibr">Benzekri et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Melia azedarach</italic> (<italic>Chinaberry Tree</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Meliacine (Glycopeptide)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B145" ref-type="bibr">Petrera and Coto, 2009</xref>; <xref rid="B11" ref-type="bibr">Barquero et al., 1997</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Labiatae</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B20" ref-type="bibr">Brand et al., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Verbenaceae</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B20" ref-type="bibr">Brand et al., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Glechon spathulata</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after viral attachment</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Bicyclogermacrene</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B193" ref-type="bibr">Venturi et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Glechon marifolia</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after viral attachment</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Bicyclogermacrene</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B193" ref-type="bibr">Venturi et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Aglaia odorata</italic> (Chinese Perfume Plant)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after viral attachment</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Moringa oleifera</italic> (Moringa)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after viral attachment</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Ventilago denticulata</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after viral attachment</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Morus alba</italic> (White Mulberry)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of early stages of viral infection</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Kuwanon X</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B119" ref-type="bibr">Ma et al., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Houttuynia cordata</italic> (Fish Mint)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of NF-&#x003ba;B activation, inhibition of viral binding, inhibition of viral entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Quercitin, Isoquercitrin and Quercitrin</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B31" ref-type="bibr">Chen et al., 2011</xref> and <xref rid="B77" ref-type="bibr">Hung et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Veratum grandiflorum</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Resveratrol</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B56" ref-type="bibr">Faith et al., 2006</xref>; <xref rid="B110" ref-type="bibr">Leyton et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Eucalyptus camaldulensis</italic> (River Red Gum)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition before and after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B120" ref-type="bibr">Mahmoud, 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Eucalyptus sideroxylon</italic> (Mugga)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of viral entry, post-infection antiviral effects</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B137" ref-type="bibr">Okba et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Eucalyptus globulus</italic> (Southern Blue Gum)</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Tereticornate A. Cypellocarpin C</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B21" ref-type="bibr">Brez&#x000e1;ni et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Cassia stipulacea</italic> (Quebracho)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Escallonia illinita</italic> (&#x000d1;ipa)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Aristotelia chilensis</italic> (Chilean Wineberry)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Drymis winteri</italic> (Winter&#x02019;s Bark)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Elytropus chilensis</italic> (Quilmay)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Luma apiculata</italic> (Chilean Myrtle)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Quillaja saponaria</italic> (Soap Bark Tree)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal, inhibition of virus binding, inhibition of virus entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B157" ref-type="bibr">Roner et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Melaleuca alternifolia</italic> (Tea Tree)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of virus binding, inhibition of virus entry</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B63" ref-type="bibr">Garozzo et al., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Melissa officinalis</italic> (<italic>Balm Mint</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B5" ref-type="bibr">Allahverdiyev et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Alpinia officinarum</italic> (<italic>Lesser Galangal</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Geum japonicum</italic> (<italic>Asian Herb Bennet</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Paeonia suffruticosa</italic> (<italic>Mudan</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Phellodendron amurense</italic> (<italic>Amur Cork Tree</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Polygala tenuifolia</italic> (<italic>Yuan Zhi</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Polygonum cuspidatum</italic> (<italic>Asian Knotweed</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Rhus javanica</italic> (<italic>Java Brucea</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Syzygium aromaticum</italic> (Clove)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Terminalia arjuna</italic> (Arjun Tree)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Terminalia chebula</italic> (Black Myrobalan)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition after virus adsorption</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown or not reported</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Alternanthera philoxeroides</italic> (Alligator Weed)</td><td valign="top" align="left" rowspan="1" colspan="1">Virucidal</td><td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and HSV-2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02713;</td><td valign="top" align="left" rowspan="1" colspan="1">Chikusetsusaponin IV</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B154" ref-type="bibr">Rattanathongkom et al., 2009</xref></td></tr></tbody></table></table-wrap></sec><sec id="S3.SS2"><title>Algae-Derived Compounds With Antiviral Activity Against HSVs in Animal Models</title><p>Griffithsin is a lectin extracted from the red alga <italic>Griffithsia</italic> sp., which has been shown to be capable of inhibiting HSV infection in a murine model of HSV-2 infection (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B136" ref-type="bibr">Nixon et al., 2013</xref>). The mechanism of action of Griffithsin consists on its binding to mannose N-glycosylations that blocks the infection process of HSV-2 and inhibits cell-to-cell spread of the virus. The results with this compound have been promising and its effectiveness is expected to be evaluated in humans in the near future. Additionally, Griffithsin has been evaluated as an antiviral in combination with carrageenan both, in cell cultures and in animals to evaluate the potential synergic effect of the two compounds against HSV-2 in a murine model of infection. The study showed a strong reduction in HSV-2 infection when applied together as a prophylactic, namely between 10 min and 1 h prior to infection (<xref rid="B109" ref-type="bibr">Levendosky et al., 2015</xref>). A more recent article reported the efficacy of Griffithsin in combination with carrageenan against HSV-2 infections together with HPV and HIV-1, which was evaluated in both, a murine and rhesus macaque model using a vaginal fast-dissolving insert (<xref rid="B47" ref-type="bibr">Derby et al., 2018</xref>). This study showed that a fast-dissolving vaginal insert with low moisture content is able to protect against SHIV in macaques, while in mice it showed promising results protecting against HSV-2 and HPV.</p><p>Notably, <italic>Symphyocladia latiuscula</italic> is a red macroalga that has been reported to produce compounds with virucidal antiviral activity against HSV-1 (<xref ref-type="fig" rid="F1">Figure 1</xref>). Vero cells infected with HSV-1 and treated with extracts from this microalga showed reduced plaque formation. The antiviral effect of these compounds has also been evaluated in a murine model skin infection, which showed decreased skin lesions compared to controls when administrated 4 h before infection and then three times per day for 6&#x02013;10 days. Also, skin obtained from these treated and infected animals showed lesser plaque forming units than the control (<xref rid="B141" ref-type="bibr">Park et al., 2014</xref>).</p><p>On the other hand, Hayashi and colleagues reported that fucoidan from the brown macroalga <italic>Undaria pinnatifida</italic>, which are sulfated polysaccharide, have antiviral activity against HSV-1 and HSV-2 that is mediated by hampering the binding of the virus to the cell surface (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B105" ref-type="bibr">Lee et al., 2004</xref>). When the effect of fucoidan was tested in another study against corneal infection with HSV-1, a reduction in herpetic lesions was found in those animals that received pretreatments with fucoidan during 1 week (<xref rid="B71" ref-type="bibr">Hayashi et al., 2008</xref>). Finally, a study performed by <xref rid="B4" ref-type="bibr">Alboofetileh et al. (2019)</xref>, showed that fucoidans extracted from the brown seaweed <italic>Nizamuddinia zanardinii</italic> exert strong antiviral activity against HSV-2 infection. They found that an algal extract containing this compound inhibited the attachment of HSV-2 to Vero cells, inhibiting the early phase of HSV-2 infection (<xref rid="B4" ref-type="bibr">Alboofetileh et al., 2019</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p><p>Another study reported that chemically modified polysaccharides from the green algae <italic>E. compressa</italic> of the <italic>Ulvaceae</italic> family, has antiviral activity against HSV-1 infection. In this work the green algae was processed and chemically modified polysaccharides were purified and tested in plaque reduction assays, determining an antiviral effect mediated after virus penetration (<xref rid="B117" ref-type="bibr">Lopes et al., 2017</xref>).</p><p>Interestingly, a recent article showed antiviral activity against HSV-2 for two purified sulfated polysaccharides isolated from the brown alga <italic>Sargassum henslowianum</italic>, a species found in southeastern China and Asia (<xref rid="B184" ref-type="bibr">Sun et al., 2019</xref>). In this work, algae extracts were treated to purify the polysaccharides named SHAP-1 and SHAP-2, which were later evaluated in viral plaque formation assay for both HSV-1 and HSV-2 virus. However, following experiments in this research article focused on HSV-2 rather than HSV-1, arguing greater clinical value for the former (<xref rid="B184" ref-type="bibr">Sun et al., 2019</xref>). Time-of-addition assays, as well and adsorption and penetration assays suggest an antiviral effect at early stages of infection (<xref rid="B184" ref-type="bibr">Sun et al., 2019</xref>).</p></sec><sec id="S3.SS3"><title>Fungus-Derived Compounds With Antiviral Activity Against HSVs in Cell Cultures</title><p>Fungus-derived compounds have also been explored for identifying novel molecules with antiviral activity against HSV-1 and HSV-2. The fungus <italic>Aspergillus versicolor</italic> has been shown to produce secondary metabolites, such as anthraquinones with anti-herpetic activity (<xref ref-type="fig" rid="F1">Figure 1</xref>). In the study by <xref rid="B76" ref-type="bibr">Huang et al. (2017)</xref>, three anthraquinones were found to have antiviral effects against HSV-1 <italic>in vitro</italic> using Vero cells. Another fungus of the <italic>Aspergillus</italic> genus showed antiviral activity against HSV-1, with two secondary metabolites flavoglaucin and isodihydroauroglaucin derived from <italic>A. ruber</italic> being assessed, and two compounds showing anti-HSV-1 effects (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B113" ref-type="bibr">Liang et al., 2018</xref>). In another study, peptides produced by the marine-derived fungus <italic>Scytalidium</italic> were found to have antiviral activity against HSV-1 and HSV-2, particularly by a peptide named Halovir, which was suggested to have virucidal activity when in direct contact with HSV-1 and HSV-2 (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B159" ref-type="bibr">Rowley et al., 2003</xref>).</p><p>Furthermore, an aqueous extract from <italic>Inonotus obliquus</italic> (AEIO) was shown to inhibit HSV-1 infection in Vero cells (<xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref>). the antiviral activity was detected at early times during viral infection, suggesting AEIO blocks viral entry, particularly membrane fusion (<xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref>).</p><p>Interestingly, fungus proteins that inhibit HSV infection have also been identified. Two proteins that bind polysaccharides from the mushroom <italic>Ganoderma lucidum</italic> were found to have antiviral effects against HSV-1 and HSV-2. One was named the neutral protein bound to polysaccharide (NPBP) and the other the acidic protein bound to polysaccharide (APBP). Although APBP had more potent antiviral activity than NPBP, both inhibited plaque formation by both types of HSV. Interestingly, it was found that the mechanism of action of APBP was mediated by the inhibition of the attachment and penetration of the virus into Vero cells (<xref rid="B54" ref-type="bibr">Eo et al., 2000</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p></sec><sec id="S3.SS4"><title>Fungus-Derived Compounds With Antiviral Activity Against HSVs in Animal Models</title><p>Sulfated compounds isolated from a polysaccharide (MI-S) derived from <italic>Agaricus brasiliensis</italic> have shown antiherpetic activity against HSV-1 and HSV-2 (<xref rid="B45" ref-type="bibr">De Sousa Cardozo et al., 2014</xref>). MI-S inhibited viral adsorption and penetration into Vero cells and had a synergistic effect with acyclovir (<xref rid="B45" ref-type="bibr">De Sousa Cardozo et al., 2014</xref>). Interestingly, this compound was also shown to reduce the severity of HSV-2 disease in a murine genital infection model with one single application (<xref rid="B26" ref-type="bibr">Cardozo et al., 2013</xref>).</p><p>On the other hand, Qing et al., reported that a protein from <italic>Grifola frondosa</italic> (GFAHP) had antiviral activity against HSV-1, which was shown to have virucidal effects in cell cultures and suppressed viral entry into Vero cells (<xref rid="B67" ref-type="bibr">Gu et al., 2007</xref>). Furthermore, GFAHP also showed antiviral activity against HSV-1 in animals when applied topically to the cornea of mice. Mice treated with GFAHP had a significant reduction in blepharitis, vascularization and stromal disease, as well as reduced viral replication in the cornea (<xref rid="B67" ref-type="bibr">Gu et al., 2007</xref>). Notably, the antiviral protein RC28 obtained from the fungus <italic>Rozites caperata</italic> showed antiviral activity against HSV-1 in Vero cells (<xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref>). Moreover, the authors evaluated the antiviral effect of RC28 in an animal model and observed that this peptide decreased the severity of stromal keratitis (<xref rid="B148" ref-type="bibr">Pradeep et al., 2019</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p></sec><sec id="S3.SS5"><title>Plant-Derived Compounds With Antiviral Activity Against HSVs in Cell Cultures</title><p>Plant extracts have received particular attention when searching for new molecules with anti-herpetic activity (<xref rid="B111" ref-type="bibr">Li et al., 2017</xref>; <xref rid="B2" ref-type="bibr">Akram et al., 2018</xref>). Interestingly, numerous plant-derived extracts and compounds have been reported to inhibit HSV replication. For instance, organic extracts belonging to the <italic>Peganum harmala</italic> species have been described to have antiviral activity against HSV-2 and to interfere with virus entry (<xref rid="B16" ref-type="bibr">Benzekri et al., 2018</xref>).</p><p>Essential oils extracted from plants belonging to the <italic>Labiatae</italic> and <italic>Verbenaceae</italic> families have also been shown to have antiviral activity against HSV. Vero cells incubated with HSV and plant-extracted essential oils for 48&#x02013;72 h significantly reduced HSV-1 and HSV-2 viral titers. Interestingly, their mechanisms of action were found to be related to the pre-infective stages (<xref rid="B20" ref-type="bibr">Brand et al., 2016</xref>). Another study that also assessed essentials oils, but extracted from <italic>Glechon spathulata</italic> and <italic>Glechon marifolia</italic> identified antiviral activity against HSV-1, which was effective after the infection of Vero cells (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B193" ref-type="bibr">Venturi et al., 2015</xref>). Eucalyptus essential oils are used to treat symptoms during cough and bronchitis, in numerous presentations, such as ointments, liniments, in oral form and in vapor baths as inhalants (<xref rid="B89" ref-type="bibr">Kaur et al., 2013</xref>). The main components of the essential oils from the Eucalyptus species are cineole and alpha-pinene (<xref rid="B168" ref-type="bibr">Sebei et al., 2015</xref>). One study evaluated the Australian tea tree oil and Eucalyptus oil over HSV and reported antiviral activity against both, HSV-1 and HSV-2. Treatments before, during or post-infection determined that these compounds had virucidal activity affecting the virus before or during adsorption, before the virus had entered the cells (<xref rid="B166" ref-type="bibr">Schnitzler et al., 2001</xref>). Ethanolic extracts from the leaves of <italic>E. camaldulensis</italic> were shown to inhibit HSV-1 and HSV-2 infection when the extracts were added to Vero cells during- and post-infection. Additionally, in this study a synergistic effect between acyclovir and the ethanolic extracts was reported in cell cultures (<xref rid="B1" ref-type="bibr">Abu-Jafar and Mahmoud, 2017</xref>). In another study, researchers reported 24 new metabolites in the leaves of <italic>E. sideroxylon</italic> and four new metabolites within the genus <italic>Eucalyptus</italic> that have antiviral activity using an ultra-performance liquid chromatography coupled to photodiode-array and electrospray ionization mass spectrometer (UPLC/PDA/ESI-qTOF-MS). Within the antiviral activities detected, there were compounds that also inhibited hepatitis A, coxsackie and adenoviruses, besides HSV-1 and HSV-2. Interestingly, the highest antiviral activity was observed against HSV-2, with the antiviral effect acting pre-treatment (virucidal), thus inhibiting virus entry and subsequent infection processes, while the antiviral effect against HSV-1 was only observed when the extract was incubated with the virus previous to the cell infection (<xref rid="B137" ref-type="bibr">Okba et al., 2017</xref>). In addition, twelve compounds isolated from the leaves and twigs of <italic>E. globulus</italic> were found to have antiviral activity against HSV-1 and HSV-2. In this study, Tereticornate A was identified to have the greatest activity against HSV-1, which was higher than acyclovir. Cypellocarpin C displayed the strongest antiviral activity against HSV-2, greater than that observed for acyclovir (<xref rid="B21" ref-type="bibr">Brez&#x000e1;ni et al., 2018</xref>).</p><p>Other essential oils, particularly those obtained from the leaves of <italic>Melissa officinalis</italic>, which is better known as lemon balm, have also been shown to have antiviral activity against both, HSV-1 and HSV-2 with the antiviral activity attributed to tannins and non-tannin polyphenolic fractions within the extract (<xref rid="B125" ref-type="bibr">Mazzanti et al., 2008</xref>). Another study determined that volatile oils from <italic>M. officinalis</italic> Lamiaceae had antiviral activity against HSV-2 (<xref rid="B5" ref-type="bibr">Allahverdiyev et al., 2004</xref>). On the other hand, extracts from <italic>Aglaia odorata</italic>, <italic>Moringa oleifera</italic>, and <italic>Ventilago denticulate</italic> have also been shown to have antiviral activity against wild-type and drug-resistant HSV-1 isolates, yet the mechanisms of action seems to not have been identified yet, or reported (<xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref>).</p><p>Plants used in traditional Chinese medicine have also been tested and found to have antiviral activity (<xref rid="B62" ref-type="bibr">Ganjhu et al., 2015</xref>). Recently, a study reported that leaves from Mulberry (<italic>Morus alba</italic> L.), a plant that is common in Asia, has antiviral properties against HSV-1 and HSV-2. The active compound within this plant has been reported to be Kuwanon X, a stilbene polyphenol derivative, which has antiviral activity over HSV at multiple steps of the infection process, inhibiting cellular adsorption and penetration, as well as the expression of HSV-1 immediate early and late genes, and the synthesis of HSV-1 DNA (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B119" ref-type="bibr">Ma et al., 2016</xref>). Another study showed that aqueous extracts from <italic>Houttuynia cordata</italic>, a Chinese herbal medicine, blocks HSV-2 infection by inhibiting NF-&#x003ba;B activation, a host transcription factor that has been reported to be required for effective HSV infection (<xref rid="B6" ref-type="bibr">Amici et al., 2006</xref>). In order to identify the compounds with antiviral activity within <italic>H. cordata</italic>, several flavonoid compounds in this plant were evaluated individually to determine their capacity to block the replication cycle of HSV-2. Quercetin, quercitrin, and isoquercitrin, the major flavonoid compounds found within <italic>H. cordata</italic> were found to be strong inhibitors of HSV-2 activity (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B31" ref-type="bibr">Chen et al., 2011</xref>). A subsequent study from another group determined that the mechanism of action behind the anti-herpetic activity of <italic>H. cordata</italic> occurred at multiple levels, such as at the adsorption level, entry, post-infection acting over NF-&#x003ba;B and had virucidal activity (<xref rid="B77" ref-type="bibr">Hung et al., 2015</xref>). Another stilbene compound that inhibits NF-&#x003ba;B activation is resveratrol, which was isolated from <italic>Veratum grandiflorum</italic> (<xref rid="B30" ref-type="bibr">Chen et al., 2012</xref>), and it is the main bioactive compound found in berries, peanuts, legumes and other plant-derived matrices, as well as red wine. Several studies have reported antiviral properties for this compound over the replication cycles of ACV-resistant and wild-type HSV-1 and HSV-2, both in cell cultures and in animal models (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B56" ref-type="bibr">Faith et al., 2006</xref>; <xref rid="B110" ref-type="bibr">Leyton et al., 2015</xref>).</p><p>Aqueous and hydroalcoholic extracts derived from native plants of Chile have also been investigated for their antiviral activity against HSV-1 and HSV-2. Hydroalcoholic extracts of <italic>Cassia stipulacea</italic> and <italic>Escallonia illinita</italic> displayed antiviral activity against HSV-1, while hydroalcoholic extracts from <italic>Aristotelia chilensis</italic>, <italic>Drymis winteri</italic>, <italic>Elytropus chilensis</italic>, as well as an aqueous extract from <italic>Luma apiculata</italic> showed antiviral activity against HSV-2. The active antiviral compounds within these preparations have not been identified or reported yet (<xref rid="B139" ref-type="bibr">Pacheco et al., 1993</xref>). In addition, another group determined that aqueous extracts from <italic>Quillaja saponaria</italic>, a Chilean soapbark tree that is endemic in the central zone of Chile, has antiviral activity against HSV-1 and other viruses. This extract, which is currently used in food and beverages was reported to have virucidal activity by blocking the attachment of viruses to the cell surface (<xref rid="B157" ref-type="bibr">Roner et al., 2007</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p></sec><sec id="S3.SS6"><title>Plant-Derived Compounds With Antiviral Activity Against HSVs in Animal Models</title><p>Several studies have assessed the antiviral effects of plant-derived compounds against herpes simplex virus in animal models either, alone or combined with acyclovir. One of these studies found that each of the following, <italic>Geum japonicum</italic> Thunb., <italic>Rhus javanica</italic> L., <italic>Syzygium aromaticum</italic> (L.), or <italic>Terminalia chebula Retzus</italic> displayed increased antiviral activity against HSV-1 when combined with acyclovir, as compared to acyclovir alone (<xref rid="B97" ref-type="bibr">Kurokawa et al., 1995</xref>). On the other hand, extracts from <italic>A. odorata</italic>, <italic>M. oleifera</italic>, and <italic>V. denticulate</italic> were shown to have antiviral effects against HSV-1 upon cutaneous infections in BALB/c mice. Here, the plant extracts combined with ACV and orally administered to the mice were shown to hamper the development and progression of HSV-1 skin lesions and increased the mean survival times of the animals (<xref rid="B114" ref-type="bibr">Lipipun et al., 2003</xref>). Chikusetsusaponin IV, a compound extracted from <italic>Alternanthera philoxeroides</italic> has shown to have antiviral activity against HSV-2 when the compound is added to the inoculum for 1 h before viral infection or immediately after viral infection (<xref rid="B154" ref-type="bibr">Rattanathongkom et al., 2009</xref>). The authors suggested that the mechanism of action of the antiviral activity action of Chikusetsusaponin IV was virucidal (<xref rid="B154" ref-type="bibr">Rattanathongkom et al., 2009</xref>). Moreover, Chikusetsusaponin IV showed antiviral activity against HSV-2 genital infection in mice when administrated three times per day three days before infection and up to 7 days after infection (<xref rid="B154" ref-type="bibr">Rattanathongkom et al., 2009</xref>). Finally, Meliacine (MA) a glycopeptide obtained from <italic>Melia azedarach</italic> has been reported to have antiviral activity against acyclovir-sensitive and acyclovir-resistant HSV-1 (<xref rid="B11" ref-type="bibr">Barquero et al., 1997</xref>). Furthermore, MA showed favorable results against HSV-2 in a mouse model of infection when applied topically immediately after infection with HSV-2 (<xref rid="B145" ref-type="bibr">Petrera and Coto, 2009</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes the antiviral activity of these compounds.</p></sec></sec><sec id="S4"><title>Clinical Trials</title><p>Different natural compounds have been tested in clinical trials following studies performed in animal models, in such a way to validate potential new drugs for the treatment of herpes simplex virus manifestations. Regarding <italic>herpes labialis</italic>, a Neem tree-based cream (<italic>Azadirachta indica</italic>) called TheraNeem Lip Therapy that has several botanical extracts, including those obtained from organic Neem Oil, organic Coconut Oil, organic Beeswax, organic Jojoba Oil, shea Butter, sesame Oil, essential Oil of Peppermint, Vitamin E (Tocopherol) was reported to having been tested in a clinical trial (<ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov">Clinicaltrials.gov</ext-link> Identifier NCT00985335). Regretfully, the results of this study have not been published to the best of our knowledge.</p><p>Another study involving the treatment of <italic>herpes labialis</italic> lesions was performed with Huanglian-Jiedu Decoction, a Chinese medicine formulation that includes four kinds of Chinese herbs; Huanglian (<italic>Rhizoma coptidis</italic>), Huangbo (<italic>Cortex Phellodendri</italic>), Huangqin (<italic>Scutellaria baicalensis</italic>) and Zhizi (<italic>Scutellaria baicalensis</italic>) (<ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov">Clinicaltrials.gov</ext-link> Identifier NCT03469232). However, similar to the clinical study reported above, the results of this trial have not been published to date.</p><p>Additionally, a randomized controlled open-label superiority trial for herpes simplex virus labial episodes was recently performed with medical-grade kanuka honey (<xref rid="B169" ref-type="bibr">Semprini et al., 2019</xref>). Here, the botanical compound and acyclovir were applied topically as a cream up to five times a day and concluded that the medical-grade kanuka honey did not provide better efficacy than acyclovir 5% (<xref rid="B169" ref-type="bibr">Semprini et al., 2019</xref>).</p><p>On the other hand, a clinical study tested VIBLOCK, which is reportedly 100% formulated with natural products, although the composition of this cream was not described (<ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov">Clinicaltrials.gov</ext-link> Identifier NCT03080961). The formulation tested the capacity of the formulated cream to prevent HSV-2 infection. However, the results of this study have not been reported.</p></sec><sec id="S5"><title>Concluding Remarks</title><p>Taken together, numerous botanical compounds derived from algae, fungi and plants have been reported to have strong antiviral activities both, in cell culture assays and in animal studies against herpes simplex viruses (HSV-1 and HSV-2). Interestingly, several mechanisms of action for these compounds have been identified, among which the most frequent seems to be virucidal activity. Other reported activities are inhibition of virus-entry into the target cells, inhibition of viral protein expression and interference with viral DNA replication, which are all essential processes for generating novel infectious viral particles (<xref rid="B79" ref-type="bibr">Ib&#x000e1;&#x000f1;ez et al., 2017</xref>).</p><p>For botanical extracts in which the active compounds against HSV-1 and HSV-2 have not been purified or identified, their clinical application seems most likely oriented toward topical treatments for cutaneous or mucosal manifestations elicited by these viruses, although some have been shown to be effective if taken orally.</p><p>Importantly, botanical drugs derived from botanical extracts and compounds can undergo special health-regulatory conditions that favor their progress into the clinic in countries such as the United States, as botanical drugs that are marketed in this country as a dietary supplements may move forward into clinical studies without the need of non-clinical pharmacological/toxicological testing if they have already been proven to have a general recognition of safety (Botanical Drug Development Guidance for Industry, December 2016, Pharmaceutical Quality/CMC). Indeed, some botanical drug products may not require typical Phase 1 tolerability studies if the sponsors can provide adequate justification for the relevance of the prior use in humans and may eventually even be commercialized over-the-counter (OTC). Hence, such indications may significantly help botanical drugs rapidly reach the clinic and help treat both ACV-sensitive and antiviral-resistant HSV isolates. Taken together, botanical compounds have the advantage, over other synthetic drugs that they are generally recognized as safe, beneficial and are readily available resources, thus reducing the pricy steps needed for new drug discovery (<xref rid="B140" ref-type="bibr">Pan et al., 2013</xref>; <xref rid="B188" ref-type="bibr">Thomford et al., 2018</xref>). Furthermore, botanical-based remedies may be low-cost alternatives for unprivileged nations, if the botanicals are available, where access to modern medicine is difficult (<xref rid="B170" ref-type="bibr">Shaikh and Hatcher, 2005</xref>; <xref rid="B88" ref-type="bibr">Karunamoorthi et al., 2013</xref>). Botanical drugs also have the advantage, over standard small molecule drugs, that they have multiple bioactive compounds that may act synergistically to hamper virus replication, while avoiding antiviral resistance (<xref rid="B205" ref-type="bibr">Yuan et al., 2016</xref>; <xref rid="B37" ref-type="bibr">Chugh et al., 2018</xref>).</p><p>However, botanical drug interactions with other drugs have been reported and undesirable side effects may occur (<xref rid="B185" ref-type="bibr">Tachjian et al., 2010</xref>; <xref rid="B52" ref-type="bibr">Ekor, 2014</xref>; <xref rid="B106" ref-type="bibr">Lee et al., 2016</xref>; <xref rid="B18" ref-type="bibr">Borse et al., 2019</xref>). At present, the World Health Organization has developed guidelines to reinforce safety monitoring of botanical medicines using pharmacovigilance systems, as well as encouraging quality controls during production by using modern manufacture techniques and applying good manufacturing practices (<xref rid="B198" ref-type="bibr">WHO, 2000</xref>, <xref rid="B199" ref-type="bibr">2004</xref>).</p><p>Finally, the expansion of the botanical drug market has attracted significant interest from pharmaceutical companies, which have intensified their development of pre-clinical and pharmacological studies on such drugs forecasting a 6.1% CAGR growth of approximately 31.6 billion dollars for this field in the period between 2017 and 2022 (<xref rid="B121" ref-type="bibr">Market Watch, 2017</xref>). Hence, a steady increase in botanical drugs reaching the market should be expected in the years to come.</p></sec><sec id="S6"><title>Author Contributions</title><p>All authors wrote the manuscript, designed the tables, and reviewed the manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by the Millennium Institute on Immunology and Immunotherapy (P09/016-F), FONDECYT grant #1190864, the &#x0201c;Fondo de Fomento al Desarrollo Tecnol&#x000f3;gico&#x0201d; (FONDEF) ID17I10143, and MA Far&#x000ed;as is an ANID (CONICYT) fellow #21191390.</p></fn></fn-group><fn-group><fn id="footnote1"><label>1</label><p><ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/news/releases/2015/herpes/en/">http://www.who.int/mediacentre/news/releases/2015/herpes/en/</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Jafar</surname><given-names>A.</given-names></name><name><surname>Mahmoud</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activity of Eucalyptus camaldulensis leaves ethanolic extract on herpes viruses infection.</article-title>
<source><italic>Int. J. Clin. Virol.</italic></source>
<volume>1</volume>
<fpage>001</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akram</surname><given-names>M.</given-names></name><name><surname>Tahir</surname><given-names>I. M.</given-names></name><name><surname>Shah</surname><given-names>S. M. A.</given-names></name><name><surname>Mahmood</surname><given-names>Z.</given-names></name><name><surname>Altaf</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review.</article-title>
<source><italic>Phyther. Res.</italic></source>
<volume>32</volume>
<fpage>811</fpage>&#x02013;<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6024</pub-id>
<?supplied-pmid 29356205?><pub-id pub-id-type="pmid">29356205</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Al-Badr</surname><given-names>A. A.</given-names></name><name><surname>Ajarim</surname><given-names>T. D. S.</given-names></name></person-group> (<year>2018</year>). &#x0201c;<article-title>Ganciclovir</article-title>,&#x0201d; in <source><italic>Profiles of Drug Substances, Excipients and Related Methodology</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Brittain</surname><given-names>H. G.</given-names></name></person-group> (<publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>).</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alboofetileh</surname><given-names>M.</given-names></name><name><surname>Rezaei</surname><given-names>M.</given-names></name><name><surname>Tabarsa</surname><given-names>M.</given-names></name><name><surname>Ritt&#x000e0;</surname><given-names>M.</given-names></name><name><surname>Donalisio</surname><given-names>M.</given-names></name><name><surname>Mariatti</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effect of different non-conventional extraction methods on the antibacterial and antiviral activity of fucoidans extracted from Nizamuddinia zanardinii.</article-title>
<source><italic>Int. J. Biol. Macromol.</italic></source>
<volume>124</volume>
<fpage>131</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.11.201</pub-id>
<?supplied-pmid 30471396?><pub-id pub-id-type="pmid">30471396</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allahverdiyev</surname><given-names>A.</given-names></name><name><surname>Duran</surname><given-names>N.</given-names></name><name><surname>Ozguven</surname><given-names>M.</given-names></name><name><surname>Koltas</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Antiviral activity of the volatile oils of <italic>Melissa officinalis</italic> L. against Herpes simplex virus type-2.</article-title>
<source><italic>Phytomedicine</italic></source>
<volume>11</volume>
<fpage>657</fpage>&#x02013;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2003.07.014</pub-id>
<?supplied-pmid 15636181?><pub-id pub-id-type="pmid">15636181</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amici</surname><given-names>C.</given-names></name><name><surname>Rossi</surname><given-names>A.</given-names></name><name><surname>Costanzo</surname><given-names>A.</given-names></name><name><surname>Ciafr&#x000e8;</surname><given-names>S.</given-names></name><name><surname>Marinari</surname><given-names>B.</given-names></name><name><surname>Balsamo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Herpes simplex virus disrupts NF-&#x003ba;B regulation by blocking its recruitment on the I&#x003ba;B&#x003b1; promoter and directing the factor on viral genes.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>281</volume>
<fpage>7110</fpage>&#x02013;<lpage>7117</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m512366200</pub-id>
<?supplied-pmid 16407234?><pub-id pub-id-type="pmid">16407234</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arduino</surname><given-names>P. G.</given-names></name><name><surname>Porter</surname><given-names>S. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features.</article-title>
<source><italic>J. Oral. Pathol. Med.</italic></source>
<volume>37</volume>
<fpage>107</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0714.2007.00586.x</pub-id>
<?supplied-pmid 18197856?><pub-id pub-id-type="pmid">18197856</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>R. L.</given-names></name><name><surname>Ashley</surname><given-names>R. L.</given-names></name><name><surname>Militoni</surname><given-names>J.</given-names></name><name><surname>Militoni</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>F.</given-names></name><name><surname>Lee</surname><given-names>F.</given-names></name><etal/></person-group> (<year>1988</year>). <article-title>Comparison of Western blot and glycoprotein G-specific immunodot enzyme assay for detecting HSV-1 and HSV-2 antibodies in human sera.</article-title>
<source><italic>J. Clin Microbiol.</italic></source>
<volume>26</volume>
<fpage>662</fpage>&#x02013;<lpage>667</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.26.4.662-667.1988</pub-id>
<?supplied-pmid 2835389?><pub-id pub-id-type="pmid">2835389</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>T. H.</given-names></name><name><surname>Boon</surname><given-names>R. J.</given-names></name><name><surname>Schultz</surname><given-names>M.</given-names></name><name><surname>Hodges-Savola</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>46</volume>
<fpage>3042</fpage>&#x02013;<lpage>3044</lpage>. <pub-id pub-id-type="doi">10.1128/aac.46.9.3042-3044.2002</pub-id>
<?supplied-pmid 12183267?><pub-id pub-id-type="pmid">12183267</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>T. H.</given-names></name><name><surname>Levin</surname><given-names>M. J.</given-names></name><name><surname>Leary</surname><given-names>J. J.</given-names></name><name><surname>Sarisky</surname><given-names>R. T.</given-names></name><name><surname>Sutton</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>16</volume>
<fpage>114</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1128/cmr.16.1.114-128.2003</pub-id>
<?supplied-pmid 12525428?><pub-id pub-id-type="pmid">12525428</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barquero</surname><given-names>A. A.</given-names></name><name><surname>Alche</surname><given-names>L. E.</given-names></name><name><surname>Coto</surname><given-names>C. E.</given-names></name></person-group> (<year>1997</year>). <article-title>Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of Herpes simplex virus type 1 alone and in combination with acyclovir.</article-title>
<source><italic>Int. J. Antimicrob. Agents</italic></source>
<volume>9</volume>
<fpage>49</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/s0924-8579(97)00023-x</pub-id>
<?supplied-pmid 18611819?><pub-id pub-id-type="pmid">18611819</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bean</surname><given-names>B.</given-names></name></person-group> (<year>1992</year>). <article-title>Antiviral therapy: current concepts and practices.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>5</volume>
<fpage>146</fpage>&#x02013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1128/cmr.5.2.146</pub-id>
<?supplied-pmid 1576586?><pub-id pub-id-type="pmid">1576586</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;lec</surname><given-names>L.</given-names></name><name><surname>Tevi-benissan</surname><given-names>C.</given-names></name><name><surname>Bianchi</surname><given-names>A.</given-names></name><name><surname>Cotigny</surname><given-names>S.</given-names></name><name><surname>Beumont-mauviel</surname><given-names>M.</given-names></name><name><surname>Si-mohamed</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>In vitro inactivation of <italic>Chlamydia trachomatis</italic> and of a panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the spermicide benzalkonium chloride.</article-title>
<source><italic>J. Antimicrob. Chemother.</italic></source>
<volume>47</volume>
<fpage>685</fpage>&#x02013;<lpage>693</lpage>. <pub-id pub-id-type="doi">10.1093/jac/46.5.685</pub-id>
<?supplied-pmid 11062186?><pub-id pub-id-type="pmid">11062186</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belshe</surname><given-names>R. B.</given-names></name><name><surname>Leone</surname><given-names>P. A.</given-names></name><name><surname>Bernstein</surname><given-names>D. I.</given-names></name><name><surname>Wald</surname><given-names>A.</given-names></name><name><surname>Levin</surname><given-names>M. J.</given-names></name><name><surname>Stapleton</surname><given-names>J. T.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Efficacy results of a trial of a herpes simplex vaccine.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>366</volume>
<fpage>34</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1103151</pub-id>
<?supplied-pmid 22216840?><pub-id pub-id-type="pmid">22216840</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname><given-names>J.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Ashley</surname><given-names>R.</given-names></name></person-group> (<year>1994</year>). <article-title>Recurrence rates in genital herpes after symptomatic first-episode infection.</article-title>
<source><italic>Ann. Intern. Med.</italic></source>
<volume>121</volume>
<fpage>847</fpage>&#x02013;<lpage>854</lpage>. <?supplied-pmid 7978697?><pub-id pub-id-type="pmid">7978697</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzekri</surname><given-names>R.</given-names></name><name><surname>Bouslama</surname><given-names>L.</given-names></name><name><surname>Papetti</surname><given-names>A.</given-names></name><name><surname>Hammami</surname><given-names>M.</given-names></name><name><surname>Smaoui</surname><given-names>A.</given-names></name><name><surname>Limam</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Anti HSV-2 activity of <italic>Peganum harmala</italic> (L.) and isolation of the active compound.</article-title>
<source><italic>Microb. Pathog.</italic></source>
<volume>114</volume>
<fpage>291</fpage>&#x02013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.12.017</pub-id>
<?supplied-pmid 29223449?><pub-id pub-id-type="pmid">29223449</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blot</surname><given-names>N.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Young</surname><given-names>P.</given-names></name><name><surname>Janvresse</surname><given-names>C.</given-names></name><name><surname>Dehesdin</surname><given-names>D.</given-names></name><name><surname>Tron</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant.</article-title>
<source><italic>Bone Marrow Transplant.</italic></source>
<volume>26</volume>
<fpage>903</fpage>&#x02013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bmt.1702591</pub-id>
<?supplied-pmid 11081393?><pub-id pub-id-type="pmid">11081393</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borse</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>D.</given-names></name><name><surname>Nivsarkar</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Understanding the relevance of herb&#x02013;drug interaction studies with special focus on interplays: a prerequisite for integrative medicine.</article-title>
<source><italic>Porto Biomed. J.</italic></source>
<volume>4</volume>:<issue>e15</issue>. <pub-id pub-id-type="doi">10.1016/j.pbj.0000000000000015</pub-id>
<?supplied-pmid 31595257?><pub-id pub-id-type="pmid">31595257</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>M. R.</given-names></name><name><surname>Safrin</surname><given-names>S.</given-names></name><name><surname>Kern</surname><given-names>E. R.</given-names></name></person-group> (<year>1993</year>). <article-title>Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern.</article-title>
<source><italic>Antivir. Chem. Chemother. Suppl.</italic></source>
<volume>4</volume>
<fpage>3</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1177/095632029300401s01</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>Y. M.</given-names></name><name><surname>Roa-Linares</surname><given-names>V. C.</given-names></name><name><surname>Betancur-Galvis</surname><given-names>L. A.</given-names></name><name><surname>Dur&#x000e1;n-Garc&#x000ed;a</surname><given-names>D. C.</given-names></name><name><surname>Stashenko</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Antiviral activity of Colombian Labiatae and Verbenaceae family essential oils and monoterpenes on Human Herpes viruses.</article-title>
<source><italic>J. Essent. Oil Res.</italic></source>
<volume>28</volume>
<fpage>130</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1080/10412905.2015.1093556</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brez&#x000e1;ni</surname><given-names>V.</given-names></name><name><surname>Lel&#x000e1;kov&#x000e1;</surname><given-names>V.</given-names></name><name><surname>Hassan</surname><given-names>S. T. S.</given-names></name><name><surname>Berchov&#x000e1;-B&#x000ed;mov&#x000e1;</surname><given-names>K.</given-names></name><name><surname>Nov&#x000fd;</surname><given-names>P.</given-names></name><name><surname>Klou&#x0010d;ek</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Anti-infectivity against herpes simplex virus and selected microbes and anti-inflammatory activities of compounds isolated from Eucalyptus globulus labill.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>360</issue>. <pub-id pub-id-type="doi">10.3390/v10070360</pub-id>
<?supplied-pmid 29986399?><pub-id pub-id-type="pmid">29986399</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>P.</given-names></name><name><surname>Sasadeusz</surname><given-names>J.</given-names></name><name><surname>Carapetis</surname><given-names>J.</given-names></name><name><surname>Waters</surname><given-names>K.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group> (<year>2001</year>). <article-title>Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.</article-title>
<source><italic>Pediatr. Infect. Dis. J.</italic></source>
<volume>20</volume>
<fpage>1083</fpage>&#x02013;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1097/00006454-200111000-00016</pub-id>
<?supplied-pmid 11734717?><pub-id pub-id-type="pmid">11734717</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>C. B.</given-names></name><name><surname>Thompson</surname><given-names>C. D.</given-names></name><name><surname>Roberts</surname><given-names>J. N.</given-names></name><name><surname>Muller</surname><given-names>M.</given-names></name><name><surname>Lowy</surname><given-names>D. R.</given-names></name><name><surname>Schiller</surname><given-names>J. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Carrageenan is a potent inhibitor of papillomavirus infection.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>2</volume>:<issue>e69</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0020069</pub-id>
<?supplied-pmid 16839203?><pub-id pub-id-type="pmid">16839203</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhles</surname><given-names>W. C.</given-names></name><name><surname>Mastre</surname><given-names>B. J.</given-names></name><name><surname>Tinker</surname><given-names>A. J.</given-names></name><name><surname>Strand</surname><given-names>V.</given-names></name><name><surname>Koretz</surname><given-names>S. H.</given-names></name></person-group> (<year>1988</year>). <article-title>Ganciclovir treatment of life-or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients.</article-title>
<source><italic>Rev. Infect. Dis.</italic></source>
<volume>10</volume>
<fpage>S495</fpage>&#x02013;<lpage>S506</lpage>. <?supplied-pmid 2847286?><pub-id pub-id-type="pmid">2847286</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>F. T.</given-names></name><name><surname>Larsen</surname><given-names>I. V.</given-names></name><name><surname>Carballo</surname><given-names>E. V.</given-names></name><name><surname>Jose</surname><given-names>G.</given-names></name><name><surname>Stern</surname><given-names>R. A.</given-names></name><name><surname>Brummel</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>In vivo anti-herpes simplex virus activity of a sulfated derivative of <italic>Agaricus brasiliensis</italic> mycelial polysaccharide.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>57</volume>
<fpage>2541</fpage>&#x02013;<lpage>2549</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02250-12</pub-id>
<?supplied-pmid 23507287?><pub-id pub-id-type="pmid">23507287</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Acyclovir neurotoxicity in a peritoneal dialysis patient: report of a case and review of the pharmacokinetics of acyclovir.</article-title>
<source><italic>Am. J. Case Rep.</italic></source>
<volume>19</volume>
<fpage>1459</fpage>&#x02013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.12659/ajcr.911520</pub-id>
<?supplied-pmid 30531673?><pub-id pub-id-type="pmid">30531673</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chayavichitsilp</surname><given-names>P.</given-names></name><name><surname>Buckwalter</surname><given-names>J. V.</given-names></name><name><surname>Krakowski</surname><given-names>A. C.</given-names></name><name><surname>Friedlander</surname><given-names>S. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Herpes simplex.</article-title>
<source><italic>Pediatr. Rev.</italic></source>
<volume>30</volume>
<fpage>119</fpage>&#x02013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1542/pir.30-4-119</pub-id>
<?supplied-pmid 19339385?><pub-id pub-id-type="pmid">19339385</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis.</article-title>
<source><italic>J. Oral. Pathol. Med.</italic></source>
<volume>46</volume>
<fpage>561</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1111/jop.12534</pub-id>
<?supplied-pmid 27935123?><pub-id pub-id-type="pmid">27935123</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Qiao</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Inhibition of herpes simplex virus infection by oligomeric stilbenoids through ROS generation.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>95</volume>
<fpage>30</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.05.001</pub-id>
<?supplied-pmid 22584350?><pub-id pub-id-type="pmid">22584350</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Houttuynia cordata blocks HSV infection through inhibition of NF-&#x003ba;B activation.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>92</volume>
<fpage>341</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.09.005</pub-id>
<?supplied-pmid 21951655?><pub-id pub-id-type="pmid">21951655</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y. C.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Trang</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Potential application of the CRISPR/CAS9 system against herpesvirus infections.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>
<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3390/v10060291</pub-id>
<?supplied-pmid 29844277?><pub-id pub-id-type="pmid">29844277</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>C. C.</given-names></name><name><surname>Wang</surname><given-names>S. H.</given-names></name><name><surname>Delamere</surname><given-names>F. M.</given-names></name><name><surname>Wojnarowska</surname><given-names>F.</given-names></name><name><surname>Peters</surname><given-names>M. C.</given-names></name><name><surname>Kanjirath</surname><given-names>P. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Interventions for prevention of herpes simplex labialis (cold sores on the lips).</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>8</volume>:<issue>CD010095</issue>. <pub-id pub-id-type="doi">10.1002/14651858.CD010095.pub2</pub-id>
<?supplied-pmid 26252373?><pub-id pub-id-type="pmid">26252373</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chilukuri</surname><given-names>S.</given-names></name><name><surname>Rosen</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Management of acyclovir-resistant herpes simplex virus.</article-title>
<source><italic>Dermatol Clin.</italic></source>
<volume>21</volume>
<fpage>311</fpage>&#x02013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1016/s0733-8635(02)00093-1</pub-id>
<?supplied-pmid 12757254?><pub-id pub-id-type="pmid">12757254</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chono</surname><given-names>K.</given-names></name><name><surname>Katsumata</surname><given-names>K.</given-names></name><name><surname>Kontani</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Sudo</surname><given-names>K.</given-names></name><name><surname>Yokota</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.</article-title>
<source><italic>J. Antimicrob. Chemother.</italic></source>
<volume>65</volume>
<fpage>1733</fpage>&#x02013;<lpage>1741</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkq198</pub-id>
<?supplied-pmid 20534624?><pub-id pub-id-type="pmid">20534624</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>T. Y.</given-names></name><name><surname>Hong</surname><given-names>B. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.</article-title>
<source><italic>Ther. Clin. Risk. Manag.</italic></source>
<volume>10</volume>
<fpage>665</fpage>&#x02013;<lpage>681</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S58242</pub-id>
<?supplied-pmid 25187721?><pub-id pub-id-type="pmid">25187721</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugh</surname><given-names>N. A.</given-names></name><name><surname>Bali</surname><given-names>S.</given-names></name><name><surname>Koul</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals.</article-title>
<source><italic>Integr. Med. Res.</italic></source>
<volume>7</volume>
<fpage>109</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.imr.2018.03.005</pub-id>
<?supplied-pmid 29989061?><pub-id pub-id-type="pmid">29989061</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Adams</surname><given-names>H. G.</given-names></name><name><surname>Brown</surname><given-names>Z. A.</given-names></name><name><surname>Holmes</surname><given-names>K. K.</given-names></name></person-group> (<year>1983</year>). <article-title>Genital herpes simplex virus infections: clinical manifestations, course, and complications.</article-title>
<source><italic>Ann. Intern. Med.</italic></source>
<volume>98</volume>
<fpage>958</fpage>&#x02013;<lpage>972</lpage>.<pub-id pub-id-type="pmid">6344712</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>F. M.</given-names></name><name><surname>Johnson</surname><given-names>A. M.</given-names></name><name><surname>Ashley</surname><given-names>R.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Mindel</surname><given-names>A.</given-names></name></person-group> (<year>1994</year>). <article-title>Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations.</article-title>
<source><italic>BMJ</italic></source>
<volume>309</volume>
<fpage>1325</fpage>&#x02013;<lpage>1329</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.309.6965.1325</pub-id>
<?supplied-pmid 7866079?><pub-id pub-id-type="pmid">7866079</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crumpacker</surname><given-names>C. S.</given-names></name></person-group> (<year>1992</year>). <article-title>Mechanism of action of foscarnet against viral polymerases.</article-title>
<source><italic>Am. J. Med.</italic></source>
<volume>92</volume>(<issue>2 Suppl. 1</issue>), <fpage>3s</fpage>&#x02013;<lpage>7s</lpage>. <?supplied-pmid 1371038?><pub-id pub-id-type="pmid">1371038</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damonte</surname><given-names>E. B.</given-names></name><name><surname>Pujol</surname><given-names>C. A.</given-names></name><name><surname>Mandal</surname><given-names>P.</given-names></name><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Ghosh</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Xylans from <italic>Scinaia hatei</italic>: structural features, sulfation and anti-HSV activity.</article-title>
<source><italic>Int. J. Biol. Macromol.</italic></source>
<volume>46</volume>
<fpage>173</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2009.12.003</pub-id>
<?supplied-pmid 20026104?><pub-id pub-id-type="pmid">20026104</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Selective anti-herpesvirus agents.</article-title>
<source><italic>Antivir. Chem. Chemother.</italic></source>
<volume>23</volume>
<fpage>93</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.3851/IMP2533</pub-id>
<?supplied-pmid 23343513?><pub-id pub-id-type="pmid">23343513</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2019</year>). <article-title>Fifty years in search of selective antiviral drugs.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>62</volume>
<fpage>7322</fpage>&#x02013;<lpage>7339</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00175</pub-id>
<?supplied-pmid 30939009?><pub-id pub-id-type="pmid">30939009</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Approved antiviral drugs over the past 50 years.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>29</volume>
<fpage>695</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00102-15</pub-id>
<?supplied-pmid 27281742?><pub-id pub-id-type="pmid">27281742</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sousa Cardozo</surname><given-names>F. T. G.</given-names></name><name><surname>Camelini</surname><given-names>C. M.</given-names></name><name><surname>Leal</surname><given-names>P. C.</given-names></name><name><surname>Kratz</surname><given-names>J. M.</given-names></name><name><surname>Nunes</surname><given-names>R. J.</given-names></name><name><surname>De Mendon&#x000e7;a</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Antiherpetic mechanism of a sulfated derivative of <italic>Agaricus brasiliensis</italic> fruiting bodies polysaccharide.</article-title>
<source><italic>Intervirology</italic></source>
<volume>57</volume>
<fpage>375</fpage>&#x02013;<lpage>383</lpage>. <pub-id pub-id-type="doi">10.1159/000365194</pub-id>
<?supplied-pmid 25359160?><pub-id pub-id-type="pmid">25359160</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deray</surname><given-names>G.</given-names></name><name><surname>Martinez</surname><given-names>F.</given-names></name><name><surname>Katlama</surname><given-names>C.</given-names></name><name><surname>Levaltier</surname><given-names>B.</given-names></name><name><surname>Beaufils</surname><given-names>H.</given-names></name><name><surname>Danis</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1989</year>). <article-title>Foscarnet nephrotoxicity: mechanism, incidence and prevention.</article-title>
<source><italic>Am. J. Nephrol.</italic></source>
<volume>9</volume>
<fpage>316</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1159/000167987</pub-id>
<?supplied-pmid 2554731?><pub-id pub-id-type="pmid">2554731</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derby</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>M.</given-names></name><name><surname>Aravantinou</surname><given-names>M.</given-names></name><name><surname>Kizima</surname><given-names>L.</given-names></name><name><surname>Barnable</surname><given-names>P.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>9</volume>:<issue>1234567890</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-06349-0</pub-id>
<?supplied-pmid 30250170?><pub-id pub-id-type="pmid">30250170</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>T. H.</given-names></name><name><surname>Dunne</surname><given-names>E. F.</given-names></name><name><surname>Markowitz</surname><given-names>L. E.</given-names></name><name><surname>Weinstock</surname><given-names>H.</given-names></name><name><surname>Berman</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Assessing neonatal herpes reporting in the United States, 2000-2005.</article-title>
<source><italic>Sex Transm. Dis.</italic></source>
<volume>35</volume>
<fpage>19</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1097/olq.0b013e318162c4c6</pub-id>
<?supplied-pmid 18157062?><pub-id pub-id-type="pmid">18157062</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>Y.</given-names></name><name><surname>Ninomiya</surname><given-names>T.</given-names></name><name><surname>Hata</surname><given-names>J.</given-names></name><name><surname>Yonemoto</surname><given-names>K.</given-names></name><name><surname>Tanizaki</surname><given-names>Y.</given-names></name><name><surname>Arima</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Seroprevalence of herpes simplex virus 1 and 2 in a population-based cohort in Japan.</article-title>
<source><italic>J. Epidemiol.</italic></source>
<volume>19</volume>
<fpage>56</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.2188/jea.je20080061</pub-id>
<?supplied-pmid 19265271?><pub-id pub-id-type="pmid">19265271</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreno</surname><given-names>B.</given-names></name><name><surname>Malkin</surname><given-names>J. E.</given-names></name><name><surname>Saiag</surname><given-names>P.</given-names></name><name><surname>Batuji-Garin</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Patients&#x02019; profile, burden of disease and quality of life in recurrent herpes labialis: a survey conducted in USA and France.</article-title>
<source><italic>J. Eur. Acad. Dermatol. Venereol.</italic></source>
<volume>26</volume>
<fpage>1458</fpage>&#x02013;<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-3083.2011.04348.x</pub-id>
<?supplied-pmid 22098071?><pub-id pub-id-type="pmid">22098071</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>C. C.</given-names></name><name><surname>Cowan</surname><given-names>M. J.</given-names></name><name><surname>Horn</surname><given-names>B.</given-names></name><name><surname>Weintrub</surname><given-names>P. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Development of herpes simplex virus stomatitis during receipt of cidofovir therapy.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>49</volume>
<fpage>e92</fpage>&#x02013;<lpage>e95</lpage>. <pub-id pub-id-type="doi">10.1086/605678</pub-id>
<?supplied-pmid 19761410?><pub-id pub-id-type="pmid">19761410</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekor</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety.</article-title>
<source><italic>Front. Neurol.</italic></source>
<volume>4</volume>:<issue>177</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2013.00177</pub-id>
<?supplied-pmid 24454289?><pub-id pub-id-type="pmid">24454289</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmert</surname><given-names>D. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Treatment of common cutaneous herpes simplex virus infections.</article-title>
<source><italic>Am. Fam. Phys.</italic></source>
<volume>61</volume>
<fpage>1697</fpage>&#x02013;<lpage>1706</lpage>. <?supplied-pmid 10750877?><pub-id pub-id-type="pmid">10750877</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eo</surname><given-names>S. K.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Lee</surname><given-names>C. K.</given-names></name><name><surname>Han</surname><given-names>S. S.</given-names></name></person-group> (<year>2000</year>). <article-title>Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from <italic>Ganoderma lucidum</italic> on herpes simplex viruses.</article-title>
<source><italic>J. Ethnopharmacol.</italic></source>
<volume>72</volume>
<fpage>475</fpage>&#x02013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-8741(00)00266-x</pub-id>
<?supplied-pmid 10996289?><pub-id pub-id-type="pmid">10996289</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>T. G.</given-names></name><name><surname>Bernstein</surname><given-names>D. I.</given-names></name><name><surname>Raborn</surname><given-names>G. W.</given-names></name><name><surname>Harmenberg</surname><given-names>J.</given-names></name><name><surname>Kowalski</surname><given-names>J.</given-names></name><name><surname>Spruance</surname><given-names>S. L.</given-names></name></person-group> (<year>2000</year>). <article-title>Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>46</volume>
<fpage>1870</fpage>&#x02013;<lpage>1874</lpage>. <pub-id pub-id-type="doi">10.1128/aac.46.6.1870-1874.2002</pub-id>
<?supplied-pmid 12019102?><pub-id pub-id-type="pmid">12019102</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faith</surname><given-names>S. A.</given-names></name><name><surname>Sweet</surname><given-names>T. J.</given-names></name><name><surname>Bailey</surname><given-names>E.</given-names></name><name><surname>Booth</surname><given-names>T.</given-names></name><name><surname>Docherty</surname><given-names>J. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Resveratrol suppresses nuclear factor-&#x003ba;B in herpes simplex virus infected cells.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>72</volume>
<fpage>242</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.06.011</pub-id>
<?supplied-pmid 16876885?><pub-id pub-id-type="pmid">16876885</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faral-Tello</surname><given-names>P.</given-names></name><name><surname>Mirazo</surname><given-names>S.</given-names></name><name><surname>Dutra</surname><given-names>C.</given-names></name><name><surname>Perez</surname><given-names>A.</given-names></name><name><surname>Geis-Asteggiante</surname><given-names>L.</given-names></name><name><surname>Frabasile</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cytotoxic, virucidal, and antiviral activity of South American plant and algae extracts.</article-title>
<source><italic>ScientificWorldJournal</italic></source>
<volume>2012</volume>:<issue>174837</issue>. <pub-id pub-id-type="doi">10.1100/2012/174837</pub-id>
<?supplied-pmid 22619617?><pub-id pub-id-type="pmid">22619617</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooq</surname><given-names>A. V.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Herpes simplex epithelial and stromal keratitis: an epidemiologic update.</article-title>
<source><italic>Surv. Ophthalmol.</italic></source>
<volume>57</volume>
<fpage>448</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1016/j.survophthal.2012.01.005</pub-id>
<?supplied-pmid 22542912?><pub-id pub-id-type="pmid">22542912</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatahzadeh</surname><given-names>M.</given-names></name><name><surname>Schwartz</surname><given-names>R. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management.</article-title>
<source><italic>J. Am. Acad. Dermatol.</italic></source>
<volume>57</volume>
<fpage>736</fpage>&#x02013;<lpage>737</lpage>. <?supplied-pmid 17939933?><pub-id pub-id-type="pmid">17939933</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>H. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Herpes simplex virus antiviral drug resistance - Current trends and future prospects.</article-title>
<source><italic>J. Clin. Virol.</italic></source>
<volume>21</volume>
<fpage>261</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/s1386-6532(00)00169-4</pub-id>
<?supplied-pmid 11397663?><pub-id pub-id-type="pmid">11397663</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>D. T.</given-names></name><name><surname>McQuillan</surname><given-names>G. M.</given-names></name><name><surname>Johnson</surname><given-names>R. E.</given-names></name><name><surname>Nahmias</surname><given-names>A. J.</given-names></name><name><surname>Aral</surname><given-names>S. O.</given-names></name><name><surname>Lee</surname><given-names>F. K.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Herpes simplex virus type 2 in the United States, 1976 to 1994.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>337</volume>
<fpage>1105</fpage>&#x02013;<lpage>1111</lpage>. <?supplied-pmid 9329932?><pub-id pub-id-type="pmid">9329932</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganjhu</surname><given-names>R. K.</given-names></name><name><surname>Mudgal</surname><given-names>P. P.</given-names></name><name><surname>Maity</surname><given-names>H.</given-names></name><name><surname>Dowarha</surname><given-names>D.</given-names></name><name><surname>Devadiga</surname><given-names>S.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Herbal plants and plant preparations as remedial approach for viral diseases.</article-title>
<source><italic>VirusDisease</italic></source>
<volume>26</volume>
<fpage>225</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1007/s13337-015-0276-6</pub-id>
<?supplied-pmid 26645032?><pub-id pub-id-type="pmid">26645032</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garozzo</surname><given-names>A.</given-names></name><name><surname>Timpanaro</surname><given-names>R.</given-names></name><name><surname>Bisignano</surname><given-names>B.</given-names></name><name><surname>Furneri</surname><given-names>P. M.</given-names></name><name><surname>Bisignano</surname><given-names>G.</given-names></name><name><surname>Castro</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>In vitro antiviral activity of <italic>Melaleuca alternifolia</italic> essential oil.</article-title>
<source><italic>Lett. Appl. Microbiol.</italic></source>
<volume>49</volume>
<fpage>806</fpage>&#x02013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-765X.2009.02740.x</pub-id>
<?supplied-pmid 19843207?><pub-id pub-id-type="pmid">19843207</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>P.</given-names></name><name><surname>Dutcher</surname><given-names>J. D.</given-names></name><name><surname>Adams</surname><given-names>E. V.</given-names></name><name><surname>Sherman</surname><given-names>J. H.</given-names></name></person-group> (<year>1958</year>). <article-title>Protective effect of seaweed extracts for chicken embryos infected with influenza B or mumps virus.</article-title>
<source><italic>Proc. Soc. Exp. Biol. Med.</italic></source>
<volume>99</volume>
<fpage>590</fpage>&#x02013;<lpage>593</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-99-24429</pub-id>
<?supplied-pmid 13614432?><pub-id pub-id-type="pmid">13614432</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnann</surname><given-names>J. W.</given-names></name><name><surname>Barton</surname><given-names>N. H.</given-names></name><name><surname>Whitley</surname><given-names>R. J.</given-names></name></person-group> (<year>1983</year>). <article-title>Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications.</article-title>
<source><italic>Pharmacother. J. Hum. Pharmacol. Drug. Ther.</italic></source>
<volume>3</volume>
<fpage>275</fpage>&#x02013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1002/j.1875-9114.1983.tb03274.x</pub-id>
<?supplied-pmid 6359082?><pub-id pub-id-type="pmid">6359082</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>H. R.</given-names></name><name><surname>Godfrey</surname><given-names>N. J.</given-names></name><name><surname>Godfrey</surname><given-names>J. C.</given-names></name><name><surname>Riley</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine.</article-title>
<source><italic>Altern. Ther. Heal. Med.</italic></source>
<volume>7</volume>
<fpage>49</fpage>&#x02013;<lpage>56</lpage>. <?supplied-pmid 11347285?><pub-id pub-id-type="pmid">11347285</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>C. Q.</given-names></name><name><surname>Li</surname><given-names>J. W.</given-names></name><name><surname>Chao</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X. W.</given-names></name><name><surname>Shen</surname><given-names>Z. Q.</given-names></name></person-group> (<year>2007</year>). <article-title>Isolation, identification and function of a novel anti-HSV-1 protein from Grifola frondosa.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>75</volume>
<fpage>250</fpage>&#x02013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2007.03.011</pub-id>
<?supplied-pmid 17475344?><pub-id pub-id-type="pmid">17475344</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>K. D. P.</given-names></name><name><surname>Dietz</surname><given-names>J.</given-names></name><name><surname>Lo</surname><given-names>T. S.</given-names></name><name><surname>Johnson</surname><given-names>E. M.</given-names></name></person-group> (<year>2018</year>). <article-title>A systematic review on the efficacy of topical acyclovir, penciclovir, and docosanol for the treatment of herpes simplex labialis.</article-title>
<source><italic>EMJ Dermatol.</italic></source>
<volume>6</volume>
<fpage>118</fpage>&#x02013;<lpage>123</lpage>.</mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handel</surname><given-names>S.</given-names></name><name><surname>Klingler</surname><given-names>E. J.</given-names></name><name><surname>Washburn</surname><given-names>K.</given-names></name><name><surname>Blank</surname><given-names>S.</given-names></name><name><surname>Schillinger</surname><given-names>J. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Population-based surveillance for neonatal herpes in New York City. April 2006-September 2010.</article-title>
<source><italic>Sex. Transm. Dis.</italic></source>
<volume>38</volume>
<fpage>705</fpage>&#x02013;<lpage>711</lpage>.<pub-id pub-id-type="pmid">21844721</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>S. T. S.</given-names></name><name><surname>Masar&#x0010d;&#x000ed;kov&#x000e1;</surname><given-names>R.</given-names></name><name><surname>Berchov&#x000e1;</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Bioactive natural products with anti-herpes simplex virus properties.</article-title>
<source><italic>J. Pharm. Pharmacol.</italic></source>
<volume>67</volume>
<fpage>1325</fpage>&#x02013;<lpage>1336</lpage>. <pub-id pub-id-type="doi">10.1111/jphp.12436</pub-id>
<?supplied-pmid 26060043?><pub-id pub-id-type="pmid">26060043</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Kanekiyo</surname><given-names>K.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Defensive effects of a fucoidan from brown alga <italic>Undaria pinnatifida</italic> against herpes simplex virus infection.</article-title>
<source><italic>Int. Immunopharmacol.</italic></source>
<volume>8</volume>
<fpage>109</fpage>&#x02013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2007.10.017</pub-id>
<?supplied-pmid 18068106?><pub-id pub-id-type="pmid">18068106</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>H.-T.</given-names></name><name><surname>Woods</surname><given-names>K. L.</given-names></name><name><surname>De Boeck</surname><given-names>H.</given-names></name><name><surname>Bronson</surname><given-names>J. J.</given-names></name><name><surname>Martin</surname><given-names>J. C.</given-names></name><name><surname>Hitchcock</surname><given-names>M. J. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.</article-title>
<source><italic>Mol. Pharmacol.</italic></source>
<volume>41</volume>
<fpage>197</fpage>&#x02013;<lpage>202</lpage>. <?supplied-pmid 1310143?><pub-id pub-id-type="pmid">1310143</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>R. A. V.</given-names></name><name><surname>Perkins</surname><given-names>R. M.</given-names></name></person-group> (<year>1989</year>). <article-title>Mode of action of 9-(4-hydroxy-3-hydroxyemthylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>33</volume>
<fpage>223</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1128/aac.33.2.223</pub-id>
<?supplied-pmid 2541655?><pub-id pub-id-type="pmid">2541655</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>R. A. V.</given-names></name><name><surname>Sutton</surname><given-names>D.</given-names></name><name><surname>Boyd</surname><given-names>M. R.</given-names></name><name><surname>Harnden</surname><given-names>M. R.</given-names></name><name><surname>Jarvest</surname><given-names>R. L.</given-names></name></person-group> (<year>1989</year>). <article-title>Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir].</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>33</volume>
<fpage>1765</fpage>&#x02013;<lpage>1773</lpage>. <pub-id pub-id-type="doi">10.1128/aac.33.10.1765</pub-id>
<?supplied-pmid 2589844?><pub-id pub-id-type="pmid">2589844</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostetler</surname><given-names>K. Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>82</volume>
<fpage>84</fpage>&#x02013;<lpage>98</lpage>. <?supplied-pmid 19425198?><pub-id pub-id-type="pmid">19425198</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Nong</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus <italic>Aspergillus versicolor</italic> SCSIO 41502.</article-title>
<source><italic>Bioorg. Med. Chem. Lett.</italic></source>
<volume>27</volume>
<fpage>787</fpage>&#x02013;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2017.01.032</pub-id>
<?supplied-pmid 28129981?><pub-id pub-id-type="pmid">28129981</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>P. Y.</given-names></name><name><surname>Ho</surname><given-names>B. C.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Chang</surname><given-names>S. Y.</given-names></name><name><surname>Kao</surname><given-names>C. L.</given-names></name><name><surname>Lee</surname><given-names>S. S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title><italic>Houttuynia cordata</italic> targets the beginning stage of herpes simplex virus infection.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0115475</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0115475</pub-id>
<?supplied-pmid 25643242?><pub-id pub-id-type="pmid">25643242</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>F. J.</given-names></name><name><surname>Far&#x000ed;as</surname><given-names>M. A.</given-names></name><name><surname>Gonzalez-Troncoso</surname><given-names>M. P.</given-names></name><name><surname>Corrales</surname><given-names>N.</given-names></name><name><surname>Duarte</surname><given-names>L. F.</given-names></name><name><surname>Retamal-D&#x000ed;az</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Experimental dissection of the lytic replication cycles of herpes simplex viruses in vitro.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>9</volume>:<issue>2406</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.02406</pub-id>
<?supplied-pmid 30386309?><pub-id pub-id-type="pmid">30386309</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>F. J.</given-names></name><name><surname>Far&#x000ed;as</surname><given-names>M. A.</given-names></name><name><surname>Retamal-d&#x000ed;az</surname><given-names>A.</given-names></name><name><surname>Espinoza</surname><given-names>J. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Pharmacological induction of heme oxygenase-1 impairs nuclear accumulation of herpes simplex virus capsids upon infection.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>8</volume>:<issue>2108</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.02108</pub-id>
<?supplied-pmid 29163402?><pub-id pub-id-type="pmid">29163402</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadhav</surname><given-names>P.</given-names></name><name><surname>Kapoor</surname><given-names>N.</given-names></name><name><surname>Thomas</surname><given-names>B.</given-names></name><name><surname>Lal</surname><given-names>H.</given-names></name><name><surname>Kshirsagar</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>Antiviral potential of selected indian medicinal (Ayurvedic) plants against herpes simplex virus 1 and 2.</article-title>
<source><italic>N. Am. J. Med. Sci.</italic></source>
<volume>4</volume>
<fpage>641</fpage>&#x02013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">23272307</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>S. H.</given-names></name><name><surname>Prichard</surname><given-names>M. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>8</volume>
<fpage>54</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.06.003</pub-id>
<?supplied-pmid 25036916?><pub-id pub-id-type="pmid">25036916</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javaly</surname><given-names>K.</given-names></name><name><surname>Wohlfeiler</surname><given-names>M.</given-names></name><name><surname>Kalayjian</surname><given-names>R.</given-names></name><name><surname>Klein</surname><given-names>T.</given-names></name><name><surname>Bryson</surname><given-names>Y.</given-names></name><name><surname>Grafford</surname><given-names>K.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study.</article-title>
<source><italic>J. Acquir. Immune Defic. Syndr.</italic></source>
<volume>21</volume>
<fpage>301</fpage>&#x02013;<lpage>306</lpage>. <?supplied-pmid 10428108?><pub-id pub-id-type="pmid">10428108</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y. C.</given-names></name><name><surname>Feng</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>Y. C.</given-names></name><name><surname>Guo</surname><given-names>X. R.</given-names></name></person-group> (<year>2016</year>). <article-title>New strategies against drug resistance to herpes simplex virus.</article-title>
<source><italic>Int. J. Oral. Sci.</italic></source>
<volume>8</volume>
<fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ijos.2016.3</pub-id>
<?supplied-pmid 27025259?><pub-id pub-id-type="pmid">27025259</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>F.</given-names></name><name><surname>Zhuo</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Anti-herpes simplex virus activity of polysaccharides from <italic>Eucheuma gelatinae</italic>.</article-title>
<source><italic>World J. Microbiol. Biotechnol.</italic></source>
<volume>31</volume>
<fpage>453</fpage>&#x02013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1007/s11274-015-1798-1</pub-id>
<?supplied-pmid 25604263?><pub-id pub-id-type="pmid">25604263</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>C.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Current concepts for genital herpes simplex virus infection: diagnostics and pathogenesis of genital tract shedding.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>29</volume>
<fpage>149</fpage>&#x02013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00043-15</pub-id>
<?supplied-pmid 26561565?><pub-id pub-id-type="pmid">26561565</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalu</surname><given-names>N. N.</given-names></name><name><surname>Desai</surname><given-names>P. J.</given-names></name><name><surname>Shirley</surname><given-names>C. M.</given-names></name><name><surname>Gibson</surname><given-names>W.</given-names></name><name><surname>Dennis</surname><given-names>P. A.</given-names></name><name><surname>Ambinder</surname><given-names>R. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Nelfinavir inhibits maturation and export of herpes simplex virus 1.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>5455</fpage>&#x02013;<lpage>5461</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03790-13</pub-id>
<?supplied-pmid 24574416?><pub-id pub-id-type="pmid">24574416</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karunamoorthi</surname><given-names>K.</given-names></name><name><surname>Jegajeevanram</surname><given-names>K.</given-names></name><name><surname>Vijayalakshmi</surname><given-names>J.</given-names></name><name><surname>Mengistie</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Traditional medicinal plants: a source of phytotherapeutic modality in resource-constrained health care settings.</article-title>
<source><italic>J. Evid. Based Compl. Altern. Med.</italic></source>
<volume>18</volume>
<fpage>67</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1177/2156587212460241</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>J.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Mahajan</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Herbal medicines: possible risks and benefits.</article-title>
<source><italic>Am. J. Phytomed. Clin. Ther.</italic></source>
<volume>141104</volume>
<fpage>226</fpage>&#x02013;<lpage>239</lpage>.</mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname><given-names>M.</given-names></name><name><surname>Nemoto</surname><given-names>O.</given-names></name><name><surname>Honda</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>D.</given-names></name><name><surname>Nakayama</surname><given-names>J.</given-names></name><name><surname>Imafuku</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Amenamevir, a novel helicase&#x02013;primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study.</article-title>
<source><italic>J. Dermatol.</italic></source>
<volume>44</volume>
<fpage>1219</fpage>&#x02013;<lpage>1227</lpage>. <pub-id pub-id-type="doi">10.1111/1346-8138.13948</pub-id>
<?supplied-pmid 28681394?><pub-id pub-id-type="pmid">28681394</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaye</surname><given-names>S.</given-names></name><name><surname>Choudhary</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>Herpes simplex keratitis.</article-title>
<source><italic>Prog. Retin. Eye Res.</italic></source>
<volume>25</volume>
<fpage>355</fpage>&#x02013;<lpage>380</lpage>. <?supplied-pmid 16807055?><pub-id pub-id-type="pmid">16807055</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kimberlin</surname><given-names>D. W.</given-names></name><name><surname>Whitley</surname><given-names>R. J.</given-names></name></person-group> (<year>2007</year>). &#x0201c;<article-title>Antiviral therapy of HSV-1 and -2</article-title>,&#x0201d; in <source><italic>Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Arvin</surname><given-names>A.</given-names></name><name><surname>Campadelli-Fiume</surname><given-names>G.</given-names></name><name><surname>Mocarski</surname><given-names>E.</given-names></name><name><surname>Moore</surname><given-names>P. S.</given-names></name><name><surname>Roizman</surname><given-names>B.</given-names></name><name><surname>Whitley</surname><given-names>R.</given-names></name><etal/></person-group> (<publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University</publisher-name>).</mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinchington</surname><given-names>P. R.</given-names></name><name><surname>Leger</surname><given-names>A. J. S.</given-names></name><name><surname>Guedon</surname><given-names>J.-M. G.</given-names></name><name><surname>Hendricks</surname><given-names>R. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Herpes simplex virus and varicella zoster virus, the house guests who never leave.</article-title>
<source><italic>Herpesviridae</italic></source>
<volume>3</volume>:<issue>5</issue>. <pub-id pub-id-type="doi">10.1186/2042-4280-3-5</pub-id>
<?supplied-pmid 22691604?><pub-id pub-id-type="pmid">22691604</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleymann</surname><given-names>G.</given-names></name><name><surname>Fischer</surname><given-names>R.</given-names></name><name><surname>Betz</surname><given-names>U. A. K.</given-names></name><name><surname>Hendrix</surname><given-names>M.</given-names></name><name><surname>Bender</surname><given-names>W.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>8</volume>
<fpage>392</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1038/nm0402-392</pub-id>
<?supplied-pmid 11927946?><pub-id pub-id-type="pmid">11927946</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname><given-names>S.</given-names></name></person-group> (<year>1990</year>). <article-title>Genital herpes&#x02013;when and how to treat.</article-title>
<source><italic>Semin. Dermatol.</italic></source>
<volume>9</volume>
<fpage>133</fpage>&#x02013;<lpage>140</lpage>. <?supplied-pmid 2202409?><pub-id pub-id-type="pmid">2202409</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukhanova</surname><given-names>M. K.</given-names></name><name><surname>Korovina</surname><given-names>A. N.</given-names></name><name><surname>Kochetkov</surname><given-names>S. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Human herpes simplex virus: life cycle and development of inhibitors.</article-title>
<source><italic>Biochemistry</italic></source>
<volume>79</volume>
<fpage>1635</fpage>&#x02013;<lpage>1652</lpage>. <pub-id pub-id-type="doi">10.1134/S0006297914130124</pub-id>
<?supplied-pmid 25749169?><pub-id pub-id-type="pmid">25749169</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>M.</given-names></name><name><surname>Nagasaka</surname><given-names>K.</given-names></name><name><surname>Hirabayashi</surname><given-names>T.</given-names></name><name><surname>Uyama</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Kageyama</surname><given-names>T.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo.</article-title>
<source><italic>Antivir. Res.</italic></source>
<volume>27</volume>
<fpage>19</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/0166-3542(94)00076-k</pub-id>
<?supplied-pmid 7486956?><pub-id pub-id-type="pmid">7486956</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwant</surname><given-names>A.</given-names></name><name><surname>Rosenthal</surname><given-names>K. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.</article-title>
<source><italic>Vaccine</italic></source>
<volume>22</volume>
<fpage>3098</fpage>&#x02013;<lpage>3104</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.059</pub-id>
<?supplied-pmid 15297061?><pub-id pub-id-type="pmid">15297061</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafferty</surname><given-names>W. E.</given-names></name><name><surname>Coombs</surname><given-names>R. W.</given-names></name><name><surname>Benedetti</surname><given-names>J.</given-names></name><name><surname>Critchlow</surname><given-names>C.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name></person-group> (<year>1987</year>). <article-title>Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>316</volume>
<fpage>1444</fpage>&#x02013;<lpage>1449</lpage>. <pub-id pub-id-type="doi">10.1056/nejm198706043162304</pub-id>
<?supplied-pmid 3033506?><pub-id pub-id-type="pmid">3033506</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lea</surname><given-names>A. P.</given-names></name><name><surname>Bryson</surname><given-names>H. M.</given-names></name></person-group> (<year>1996</year>). <source><italic>Cidofovir. Drugs</italic></source>
<volume>52</volume>, <fpage>225</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-199652020-00006</pub-id>
<?supplied-pmid 8841740?><pub-id pub-id-type="pmid">8841740</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebrun-Vignes</surname><given-names>B.</given-names></name><name><surname>Bouzamondo</surname><given-names>A.</given-names></name><name><surname>Dupuy</surname><given-names>A.</given-names></name><name><surname>Guillaume</surname><given-names>J. C.</given-names></name><name><surname>Lechat</surname><given-names>P.</given-names></name><name><surname>Chosidow</surname><given-names>O.</given-names></name></person-group> (<year>2007</year>). <article-title>A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks.</article-title>
<source><italic>J. Am. Acad. Dermatol.</italic></source>
<volume>57</volume>
<fpage>238</fpage>&#x02013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2007.02.008</pub-id>
<?supplied-pmid 17416440?><pub-id pub-id-type="pmid">17416440</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C. K.</given-names></name><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Nam</surname><given-names>J. R.</given-names></name><name><surname>Lee</surname><given-names>M. J.</given-names></name><name><surname>Yim</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>H. K.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Anti-Picornavirus activity and other antiviral activity of sulfated exopolysaccharide from the marine microalga gyrodinium impudicum strain KG03.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>82</volume>
<fpage>A40</fpage>&#x02013;<lpage>A40</lpage>.</mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E.</given-names></name><name><surname>Pavy</surname><given-names>M.</given-names></name><name><surname>Young</surname><given-names>N.</given-names></name><name><surname>Freeman</surname><given-names>C.</given-names></name><name><surname>Lobigs</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>69</volume>
<fpage>31</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.08.006</pub-id>
<?supplied-pmid 16309754?><pub-id pub-id-type="pmid">16309754</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. B.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Sankawa</surname><given-names>U.</given-names></name><name><surname>Maeda</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from <italic>Monostroma latissimum</italic>.</article-title>
<source><italic>Planta Med.</italic></source>
<volume>65</volume>
<fpage>439</fpage>&#x02013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1055/s-2006-960804</pub-id>
<?supplied-pmid 10418331?><pub-id pub-id-type="pmid">10418331</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. L.</given-names></name><name><surname>Ayashi</surname><given-names>K. H.</given-names></name><name><surname>Ashimoto</surname><given-names>M. H.</given-names></name><name><surname>Akano</surname><given-names>T. N.</given-names></name><name><surname>Ayashi</surname><given-names>T. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Novel antiviral fucoidan from sporophyll of <italic>Undaria pinnatifida</italic> (Mekabu).</article-title>
<source><italic>Chem. Pharm. Bull.</italic></source>
<volume>52</volume>
<fpage>1091</fpage>&#x02013;<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.52.1091</pub-id>
<?supplied-pmid 15340195?><pub-id pub-id-type="pmid">15340195</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Jun</surname><given-names>S. A.</given-names></name><name><surname>Hong</surname><given-names>S. S.</given-names></name><name><surname>Ahn</surname><given-names>Y. C.</given-names></name><name><surname>Lee</surname><given-names>D. S.</given-names></name><name><surname>Son</surname><given-names>C. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Systematic review of adverse effects from herbal drugs reported in randomized controlled trials.</article-title>
<source><italic>Phyther. Res.</italic></source>
<volume>1419</volume>
<fpage>1412</fpage>&#x02013;<lpage>1419</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5647</pub-id>
<?supplied-pmid 27196988?><pub-id pub-id-type="pmid">27196988</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y. J.</given-names></name><name><surname>Neofytos</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>S. J.</given-names></name><name><surname>Cheteyan</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>Y. T.</given-names></name><name><surname>Papadopoulos</surname><given-names>E. B.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.</article-title>
<source><italic>Transpl. Infect. Dis.</italic></source>
<volume>20</volume>
<issue>e12977</issue>. <pub-id pub-id-type="doi">10.1111/tid.12977</pub-id>
<?supplied-pmid 30120866?><pub-id pub-id-type="pmid">30120866</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leflore</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>P. L.</given-names></name><name><surname>Fletcher</surname><given-names>C. V.</given-names></name></person-group> (<year>2000</year>). <article-title>A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections.</article-title>
<source><italic>Drug Saf.</italic></source>
<volume>23</volume>
<fpage>131</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.2165/00002018-200023020-00004</pub-id>
<?supplied-pmid 10945375?><pub-id pub-id-type="pmid">10945375</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levendosky</surname><given-names>K.</given-names></name><name><surname>Mizenina</surname><given-names>O.</given-names></name><name><surname>Martinelli</surname><given-names>E.</given-names></name><name><surname>Jean-Pierre</surname><given-names>N.</given-names></name><name><surname>Kizima</surname><given-names>L.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Griffithsin and carrageenan combination to target herpes simplex virus 2 and human papillomavirus.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>59</volume>
<fpage>7290</fpage>&#x02013;<lpage>7298</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01816-15</pub-id>
<?supplied-pmid 26369967?><pub-id pub-id-type="pmid">26369967</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyton</surname><given-names>L.</given-names></name><name><surname>Hott</surname><given-names>M.</given-names></name><name><surname>Acu&#x000f1;a</surname><given-names>F.</given-names></name><name><surname>Caroca</surname><given-names>J.</given-names></name><name><surname>Nu&#x000f1;ez</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Nutraceutical activators of AMPK/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during HSV-1 infection.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>205</volume>
<fpage>63</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2015.05.015</pub-id>
<?supplied-pmid 26031763?><pub-id pub-id-type="pmid">26031763</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Anti-herpes simplex virus type 1 activity of Houttuynoid A, a flavonoid from <italic>Houttuynia cordata</italic> Thunb.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>144</volume>
<fpage>273</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.06.010</pub-id>
<?supplied-pmid 28629987?><pub-id pub-id-type="pmid">28629987</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X. H.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>L. F.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Yan</surname><given-names>C. Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Traditional chinese medicine as a potential source for hsv-1 therapy by acting on virus or the susceptibility of host.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>19</volume>
<fpage>1</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>T. M.</given-names></name><name><surname>Fang</surname><given-names>Y. W.</given-names></name><name><surname>Zheng</surname><given-names>J. Y.</given-names></name><name><surname>Shao</surname><given-names>C. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Secondary metabolites isolated from the gorgonian-derived fungus <italic>Aspergillus ruber</italic> and their antiviral activity.</article-title>
<source><italic>Chem. Nat. Compd.</italic></source>
<volume>54</volume>
<fpage>559</fpage>&#x02013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1007/s10600-018-2406-z</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipipun</surname><given-names>V.</given-names></name><name><surname>Kurokawa</surname><given-names>M.</given-names></name><name><surname>Suttisri</surname><given-names>R.</given-names></name><name><surname>Taweechotipatr</surname><given-names>P.</given-names></name><name><surname>Pramyothin</surname><given-names>P.</given-names></name><name><surname>Hattori</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>60</volume>
<fpage>175</fpage>&#x02013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/s0166-3542(03)00152-9</pub-id>
<?supplied-pmid 14638393?><pub-id pub-id-type="pmid">14638393</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lolis</surname><given-names>M. S.</given-names></name><name><surname>Gonzalez</surname><given-names>L.</given-names></name><name><surname>Cohen</surname><given-names>P. J.</given-names></name><name><surname>Schwartz</surname><given-names>R. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Drug-resistant herpes simplex virus in HIV infected patients.</article-title>
<source><italic>Acta Dermatovenerol. Croat.</italic></source>
<volume>16</volume>
<fpage>204</fpage>&#x02013;<lpage>208</lpage>.</mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looker</surname><given-names>K. J.</given-names></name><name><surname>Garnett</surname><given-names>G. P.</given-names></name><name><surname>Schmid</surname><given-names>G. P.</given-names></name></person-group> (<year>2008</year>). <article-title>An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.</article-title>
<source><italic>Bull. World Heal. Organ.</italic></source>
<volume>86</volume>
<fpage>805</fpage>&#x02013;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.2471/blt.07.046128</pub-id>
<?supplied-pmid 18949218?><pub-id pub-id-type="pmid">18949218</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>N.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name><name><surname>Espada</surname><given-names>S. F.</given-names></name><name><surname>Bomfim</surname><given-names>W. A.</given-names></name><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Faccin-Galhardi</surname><given-names>L. C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Green seaweed <italic>Enteromorpha compressa</italic> (Chlorophyta, Ulvaceae) derived sulphated polysaccharides inhibit herpes simplex virus.</article-title>
<source><italic>Int. J. Biol. Macromol.</italic></source>
<volume>102</volume>
<fpage>605</fpage>&#x02013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.04.043</pub-id>
<?supplied-pmid 28431944?><pub-id pub-id-type="pmid">28431944</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luber</surname><given-names>A. D.</given-names></name><name><surname>Flaherty</surname><given-names>J. F.</given-names></name></person-group> (<year>1996</year>). <article-title>Famciclovir for treatment of herpesvirus infections.</article-title>
<source><italic>Ann. Pharmacother.</italic></source>
<volume>30</volume>
<fpage>978</fpage>&#x02013;<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1177/106002809603000913</pub-id>
<?supplied-pmid 8876860?><pub-id pub-id-type="pmid">8876860</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>F.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Anti-HSV activity of Kuwanon X from mulberry leaves with genes expression inhibitory and HSV-1 induced NF-&#x003ba;B deactivated properties.</article-title>
<source><italic>Biol. Pharm. Bull.</italic></source>
<volume>39</volume>
<fpage>1667</fpage>&#x02013;<lpage>1674</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b16-00401</pub-id>
<?supplied-pmid 27725444?><pub-id pub-id-type="pmid">27725444</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activity of <italic>Eucalyptus camaldulensis</italic> leaves ethanolic extract on herpes viruses infection.</article-title>
<source><italic>Int. J. Clin. Virol.</italic></source>
<volume>1</volume>
<fpage>001</fpage>&#x02013;<lpage>009</lpage>. <pub-id pub-id-type="doi">10.29328/journal.ijcv.1001001</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><collab>Market Watch</collab> (<year>2017</year>). <article-title>Market will Grow from $29.4 Billion in 2017 to Approx. $39.6 Billion by 2022 with a CAGR of 6.1%.</article-title> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.marketwatch.com">www.marketwatch.com</ext-link>
<comment>(accessed December 27, 2019)</comment>.</mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>A.</given-names></name><name><surname>Faulds</surname><given-names>D.</given-names></name></person-group> (<year>1994</year>). <article-title>Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.</article-title>
<source><italic>Drugs</italic></source>
<volume>48</volume>
<fpage>455</fpage>&#x02013;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-199448030-00009</pub-id>
<?supplied-pmid 7527763?><pub-id pub-id-type="pmid">7527763</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>M.</given-names></name><name><surname>Conant</surname><given-names>M.</given-names></name><name><surname>Hurley</surname><given-names>A.</given-names></name><name><surname>Schluger</surname><given-names>R.</given-names></name><name><surname>Duran</surname><given-names>M.</given-names></name><name><surname>Peterkin</surname><given-names>J.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 Protease, to treat HIV infection.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>177</volume>
<fpage>1533</fpage>&#x02013;<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1086/515312</pub-id>
<?supplied-pmid 9607830?><pub-id pub-id-type="pmid">9607830</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>T.</given-names></name><name><surname>Boehme</surname><given-names>R.</given-names></name></person-group> (<year>1988</year>). <article-title>Antiviral activity and mechanism of action of ganciclovir.</article-title>
<source><italic>Rev. Infect. Dis.</italic></source>
<volume>10</volume>
<fpage>S490</fpage>&#x02013;<lpage>S494</lpage>. <?supplied-pmid 2847285?><pub-id pub-id-type="pmid">2847285</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzanti</surname><given-names>G.</given-names></name><name><surname>Battinelli</surname><given-names>L.</given-names></name><name><surname>Pompeo</surname><given-names>C.</given-names></name><name><surname>Serrilli</surname><given-names>A. M.</given-names></name><name><surname>Rossi</surname><given-names>R.</given-names></name><name><surname>Sauzullo</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Inhibitory activity of <italic>Melissa officinalis</italic> L. extract on Herpes simplex virus type 2 replication.</article-title>
<source><italic>Nat. Prod. Res.</italic></source>
<volume>22</volume>
<fpage>1433</fpage>&#x02013;<lpage>1440</lpage>. <pub-id pub-id-type="doi">10.1080/14786410802075939</pub-id>
<?supplied-pmid 19023806?><pub-id pub-id-type="pmid">19023806</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>J. P.</given-names></name><name><surname>Browning</surname><given-names>W. D.</given-names></name><name><surname>Teerlink</surname><given-names>C.</given-names></name><name><surname>Veit</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Treatment of herpes labialis: comparison of two OTC drugs and untreated controls.</article-title>
<source><italic>J. Esthet. Restor. Dent.</italic></source>
<volume>24</volume>
<fpage>103</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1111/j.1708-8240.2011.00417.x</pub-id>
<?supplied-pmid 22524716?><pub-id pub-id-type="pmid">22524716</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeoch</surname><given-names>D. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Lineages of varicella-zoster virus.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>90</volume>
<fpage>963</fpage>&#x02013;<lpage>969</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.007658-0</pub-id>
<?supplied-pmid 19264671?><pub-id pub-id-type="pmid">19264671</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meira</surname><given-names>R. Z. C.</given-names></name><name><surname>Biscaia</surname><given-names>I. F. B.</given-names></name><name><surname>Nogueira</surname><given-names>C.</given-names></name><name><surname>Murakami</surname><given-names>F. S.</given-names></name><name><surname>Bernardi</surname><given-names>L. S.</given-names></name><name><surname>Oliveira</surname><given-names>P. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Solid-state characterization and compatibility studies of penciclovir, lysine hydrochloride, and pharmaceutical excipients.</article-title>
<source><italic>Materials</italic></source>
<volume>12</volume>
<issue>E3154</issue>. <pub-id pub-id-type="doi">10.3390/ma12193154</pub-id>
<?supplied-pmid 31569620?><pub-id pub-id-type="pmid">31569620</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname><given-names>S.</given-names></name><name><surname>Bravin</surname><given-names>I. C.</given-names></name><name><surname>Yokoya</surname><given-names>N. S.</given-names></name><name><surname>Villela</surname><given-names>M. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Anti-HSV activity of <italic>Hypnea musciformis</italic> cultured with different phytohormones.</article-title>
<source><italic>Rev. Bras. Farmacogn.</italic></source>
<volume>22</volume>
<fpage>789</fpage>&#x02013;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1590/s0102-695x2012005000054</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>G. J.</given-names></name><name><surname>Benedetti</surname><given-names>J.</given-names></name><name><surname>Ashley</surname><given-names>R.</given-names></name><name><surname>Selke</surname><given-names>S. A.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name></person-group> (<year>1992</year>). <article-title>Risk factors for the sexual transmission of genital herpes.</article-title>
<source><italic>Ann. Intern. Med.</italic></source>
<volume>116</volume>
<fpage>197</fpage>&#x02013;<lpage>202</lpage>. <?supplied-pmid 1309413?><pub-id pub-id-type="pmid">1309413</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>K. J.</given-names></name><name><surname>Trees</surname><given-names>D.</given-names></name><name><surname>Levine</surname><given-names>W. C.</given-names></name><name><surname>Lewis</surname><given-names>J. S.</given-names></name><name><surname>Litchfield</surname><given-names>B.</given-names></name><name><surname>Pettus</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The genital ulcer disease surveillance group.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>178</volume>
<fpage>1795</fpage>&#x02013;<lpage>1798</lpage>. <pub-id pub-id-type="doi">10.1086/314502</pub-id>
<?supplied-pmid 9815237?><pub-id pub-id-type="pmid">9815237</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mindel</surname><given-names>A.</given-names></name></person-group> (<year>1991</year>). <article-title>Is it meaningful to treat patients with recurrent herpetic infections?</article-title>
<source><italic>Scand. J. Infect. Dis. Suppl.</italic></source>
<volume>80</volume>
<fpage>27</fpage>&#x02013;<lpage>32</lpage>. <?supplied-pmid 1803498?><pub-id pub-id-type="pmid">1803498</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <source><italic>Famciclovir. xPharm: The Comprehensive Pharmacology Reference.</italic></source>
<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <fpage>1</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/B978-008055232-3.61737-4</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moomaw</surname><given-names>M. D.</given-names></name><name><surname>Cornea</surname><given-names>P.</given-names></name><name><surname>Rathbun</surname><given-names>R. C.</given-names></name><name><surname>Wendel</surname><given-names>K. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster.</article-title>
<source><italic>Expert. Rev. Anti Infect. Ther.</italic></source>
<volume>1</volume>
<fpage>283</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1586/14787210.1.2.283</pub-id>
<?supplied-pmid 15482124?><pub-id pub-id-type="pmid">15482124</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morfin</surname><given-names>F.</given-names></name><name><surname>Thouvenot</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Herpes simplex virus resistance to antiviral drugs.</article-title>
<source><italic>J. Clin. Virol.</italic></source>
<volume>26</volume>
<fpage>29</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/s1386-6532(02)00263-9</pub-id>
<?supplied-pmid 12589832?><pub-id pub-id-type="pmid">12589832</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>B.</given-names></name><name><surname>Stefanidou</surname><given-names>M.</given-names></name><name><surname>Mesquita</surname><given-names>P. M. M.</given-names></name><name><surname>Fakioglu</surname><given-names>E.</given-names></name><name><surname>Segarra</surname><given-names>T.</given-names></name><name><surname>Rohan</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>87</volume>
<fpage>6257</fpage>&#x02013;<lpage>6269</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00012-13</pub-id>
<?supplied-pmid 23536670?><pub-id pub-id-type="pmid">23536670</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okba</surname><given-names>M. M.</given-names></name><name><surname>El Gedaily</surname><given-names>R. A.</given-names></name><name><surname>Ashour</surname><given-names>R. M.</given-names></name></person-group> (<year>2017</year>). <article-title>UPLC&#x02013;PDA&#x02013;ESI&#x02013;qTOF-MS profiling and potent anti-HSV-II activity of <italic>Eucalyptus sideroxylon</italic> leaves.</article-title>
<source><italic>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</italic></source>
<volume>106</volume>
<fpage>335</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchromb.2017.10.065</pub-id>
<?supplied-pmid 29122531?><pub-id pub-id-type="pmid">29122531</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormrod</surname><given-names>D.</given-names></name><name><surname>Scott</surname><given-names>L. J.</given-names></name><name><surname>Perry</surname><given-names>C. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.</article-title>
<source><italic>Drugs</italic></source>
<volume>59</volume>
<fpage>839</fpage>&#x02013;<lpage>863</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200059040-00013</pub-id>
<?supplied-pmid 10804039?><pub-id pub-id-type="pmid">10804039</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>P.</given-names></name><name><surname>Sierra</surname><given-names>J.</given-names></name><name><surname>Schmeda-Hirschman</surname><given-names>G.</given-names></name><name><surname>Potter</surname><given-names>C. W.</given-names></name><name><surname>Jones</surname><given-names>B. M.</given-names></name><name><surname>Moshref</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Antiviral activity of chilean medicinal plant extracts.</article-title>
<source><italic>Phyther. Res.</italic></source>
<volume>7</volume>
<fpage>415</fpage>&#x02013;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2650070606</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S. Y.</given-names></name><name><surname>Zhou</surname><given-names>S. F.</given-names></name><name><surname>Gao</surname><given-names>S. H.</given-names></name><name><surname>Yu</surname><given-names>Z. L.</given-names></name><name><surname>Zhang</surname><given-names>S. F.</given-names></name><name><surname>Tang</surname><given-names>M. K.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>New perspectives on how to discover drugs from herbal medicines: CAM&#x02019;S outstanding contribution to modern therapeutics.</article-title>
<source><italic>Evid. Based Compl. Altern. Med.</italic></source>
<volume>2013</volume>:<issue>627375</issue>.</mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Kurokawa</surname><given-names>M.</given-names></name><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Nakaruma</surname><given-names>N.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Hattori</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Antiviral activity of the marine alga <italic>Symphyocladia latiuscula</italic> against Herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 Infection in Mice.</article-title>
<source><italic>Biol. Pharm. Bull.</italic></source>
<volume>28</volume>
<fpage>2258</fpage>&#x02013;<lpage>2262</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.28.2258</pub-id>
<?supplied-pmid 16327161?><pub-id pub-id-type="pmid">16327161</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patick</surname><given-names>A. K.</given-names></name><name><surname>Mo</surname><given-names>H.</given-names></name><name><surname>Markowitz</surname><given-names>M.</given-names></name><name><surname>Appelt</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Musick</surname><given-names>L.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>40</volume>
<fpage>292</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1128/aac.40.2.292</pub-id>
<?supplied-pmid 8834868?><pub-id pub-id-type="pmid">8834868</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paz-Bailey</surname><given-names>G.</given-names></name><name><surname>Ramaswamy</surname><given-names>M.</given-names></name><name><surname>Hawkes</surname><given-names>S. J.</given-names></name><name><surname>Geretti</surname><given-names>A. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Herpes simplex virus type 2: epidemiology and management options in developing countries.</article-title>
<source><italic>Postgrad. Med. J.</italic></source>
<volume>84</volume>
<fpage>299</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2006.020966</pub-id>
<?supplied-pmid 18644920?><pub-id pub-id-type="pmid">18644920</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perna</surname><given-names>J. J.</given-names></name><name><surname>Mannix</surname><given-names>M. L.</given-names></name><name><surname>Rooney</surname><given-names>J. F.</given-names></name><name><surname>Notkins</surname><given-names>A. L.</given-names></name><name><surname>Straus</surname><given-names>S. E.</given-names></name></person-group> (<year>1987</year>). <article-title>Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model.</article-title>
<source><italic>J. Am. Acad. Dermatol.</italic></source>
<volume>17</volume>
<fpage>473</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/s0190-9622(87)70232-1</pub-id>
<?supplied-pmid 2821086?><pub-id pub-id-type="pmid">2821086</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrera</surname><given-names>E.</given-names></name><name><surname>Coto</surname><given-names>C. E.</given-names></name></person-group> (<year>2009</year>). <article-title>Therapeutic effect of meliacine, an antiviral derived from <italic>Melia azedarach</italic> L., in mice genital herpetic infection.</article-title>
<source><italic>Phytother. Res.</italic></source>
<volume>23</volume>
<fpage>1771</fpage>&#x02013;<lpage>1777</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2850</pub-id>
<?supplied-pmid 19441066?><pub-id pub-id-type="pmid">19441066</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>C. L.</given-names></name><name><surname>James</surname><given-names>S. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Antiviral therapies for herpesviruses: current agents and new directions.</article-title>
<source><italic>Clin. Ther.</italic></source>
<volume>40</volume>
<fpage>1282</fpage>&#x02013;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2018.07.006</pub-id>
<?supplied-pmid 30104016?><pub-id pub-id-type="pmid">30104016</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>L. E.</given-names></name><name><surname>Marcelletti</surname><given-names>J. F.</given-names></name><name><surname>Katz</surname><given-names>L. R.</given-names></name><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Katz</surname><given-names>D. H.</given-names></name><name><surname>Parish</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process.</article-title>
<source><italic>Antivir. Res.</italic></source>
<volume>40</volume>
<fpage>85</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/s0166-3542(98)00048-5</pub-id>
<?supplied-pmid 9864049?><pub-id pub-id-type="pmid">9864049</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pradeep</surname><given-names>P.</given-names></name><name><surname>Manju</surname><given-names>V.</given-names></name><name><surname>Ahsan</surname><given-names>M. F.</given-names></name></person-group> (<year>2019</year>). &#x0201c;<article-title>Antiviral potency of mushroom constituents</article-title>,&#x0201d; in <source><italic>Medicinal Mushrooms</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Agrawal</surname><given-names>D.</given-names></name><name><surname>Dhanasekaran</surname><given-names>M.</given-names></name></person-group> (<publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>275</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-13-6382-5_10</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prichard</surname><given-names>M. N.</given-names></name><name><surname>Kern</surname><given-names>E. R.</given-names></name><name><surname>Hartline</surname><given-names>C. B.</given-names></name><name><surname>Lanier</surname><given-names>E. R.</given-names></name><name><surname>Quenelle</surname><given-names>D. C.</given-names></name></person-group> (<year>2011</year>). <article-title>CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>55</volume>
<fpage>4728</fpage>&#x02013;<lpage>4734</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00545-11</pub-id>
<?supplied-pmid 21788472?><pub-id pub-id-type="pmid">21788472</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujol</surname><given-names>C. A.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>B.</given-names></name><name><surname>Damonte</surname><given-names>E. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides.</article-title>
<source><italic>Int. J. Biol. Macromol.</italic></source>
<volume>51</volume>
<fpage>412</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2012.05.028</pub-id>
<?supplied-pmid 22652218?><pub-id pub-id-type="pmid">22652218</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quenelle</surname><given-names>D. C.</given-names></name><name><surname>Lampert</surname><given-names>B.</given-names></name><name><surname>Collins</surname><given-names>D. J.</given-names></name><name><surname>Rice</surname><given-names>T. L.</given-names></name><name><surname>Painter</surname><given-names>G. R.</given-names></name><name><surname>Kern</surname><given-names>E. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>202</volume>
<fpage>1492</fpage>&#x02013;<lpage>1499</lpage>. <pub-id pub-id-type="doi">10.1086/656717</pub-id>
<?supplied-pmid 20923374?><pub-id pub-id-type="pmid">20923374</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramchandani</surname><given-names>M.</given-names></name><name><surname>Kong</surname><given-names>M.</given-names></name><name><surname>Tronstein</surname><given-names>E.</given-names></name><name><surname>Selke</surname><given-names>S.</given-names></name><name><surname>Mikhaylova</surname><given-names>A.</given-names></name><name><surname>Magaret</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Oral mucosa of healthy adults.</article-title>
<source><italic>Sex. Trans. Dis.</italic></source>
<volume>43</volume>
<fpage>756</fpage>&#x02013;<lpage>760</lpage>.</mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>K. H.</given-names></name><name><surname>Hoon</surname><given-names>E. F.</given-names></name><name><surname>Massey</surname><given-names>J. K.</given-names></name><name><surname>Johnson</surname><given-names>J. H.</given-names></name></person-group> (<year>1990</year>). <article-title>Daily stress and recurrence of genital herpes simplex.</article-title>
<source><italic>Arch. Intern. Med.</italic></source>
<volume>150</volume>
<fpage>1889</fpage>&#x02013;<lpage>1893</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.150.9.1889</pub-id>
<?supplied-pmid 2393320?><pub-id pub-id-type="pmid">2393320</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rattanathongkom</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>J.-B.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Sripanidkulchai</surname><given-names>B.-O.</given-names></name><name><surname>Kanchanapoom</surname><given-names>T.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Evaluation of Chikusetsusaponin IVa isolated from <italic>Alternanthera philoxeroides</italic> for its potency against viral replication.</article-title>
<source><italic>Planta Med.</italic></source>
<volume>75</volume>
<fpage>829</fpage>&#x02013;<lpage>835</lpage>. <pub-id pub-id-type="doi">10.1055/s-0029-1185436</pub-id>
<?supplied-pmid 19277947?><pub-id pub-id-type="pmid">19277947</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reusser</surname><given-names>P.</given-names></name></person-group> (<year>1996</year>). <article-title>Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.</article-title>
<source><italic>J. Hosp. Infect.</italic></source>
<volume>33</volume>
<fpage>235</fpage>&#x02013;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/s0195-6701(96)90010-9</pub-id>
<?supplied-pmid 8864937?><pub-id pub-id-type="pmid">8864937</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>M.</given-names></name><name><surname>Robaina</surname><given-names>M.</given-names></name><name><surname>Mendes</surname><given-names>G.</given-names></name><name><surname>Silva</surname><given-names>T.</given-names></name><name><surname>Gestinari</surname><given-names>L.</given-names></name><name><surname>Pamplona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Antiviral activity of extracts from Brazilian seaweeds against herpes simplex virus.</article-title>
<source><italic>Rev. Bras. Farmacogn.</italic></source>
<volume>22</volume>
<fpage>714</fpage>&#x02013;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.3390/molecules18055761</pub-id>
<?supplied-pmid 23681060?><pub-id pub-id-type="pmid">23681060</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roner</surname><given-names>M. R.</given-names></name><name><surname>Sprayberry</surname><given-names>J.</given-names></name><name><surname>Spinks</surname><given-names>M.</given-names></name><name><surname>Dhanji</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Antiviral activity obtained from aqueous extracts of the Chilean soapbark tree (<italic>Quillaja saponaria</italic> Molina).</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>88</volume>
<fpage>275</fpage>&#x02013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.82321-0</pub-id>
<?supplied-pmid 17170461?><pub-id pub-id-type="pmid">17170461</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roozbahani</surname><given-names>M.</given-names></name><name><surname>Hammersmith</surname><given-names>K. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Management of herpes simplex virus epithelial keratitis.</article-title>
<source><italic>Curr. Opin. Ophthalmol.</italic></source>
<volume>29</volume>
<fpage>360</fpage>&#x02013;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1097/ICU.0000000000000483</pub-id>
<?supplied-pmid 29697435?><pub-id pub-id-type="pmid">29697435</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>D. C.</given-names></name><name><surname>Kelly</surname><given-names>S.</given-names></name><name><surname>Kauffman</surname><given-names>C. A.</given-names></name><name><surname>Jensen</surname><given-names>P. R.</given-names></name><name><surname>Fenical</surname><given-names>W.</given-names></name></person-group> (<year>2003</year>). <article-title>Halovirs A-E, new antiviral agents from a marine-derived fungus of the genus <italic>Scytalidium</italic>.</article-title>
<source><italic>Bioorgan. Med. Chem.</italic></source>
<volume>11</volume>
<fpage>4263</fpage>&#x02013;<lpage>4274</lpage>. <pub-id pub-id-type="doi">10.1016/s0968-0896(03)00395-x</pub-id>
<?supplied-pmid 12951157?><pub-id pub-id-type="pmid">12951157</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>S. L.</given-names></name><name><surname>Thisted</surname><given-names>R. A.</given-names></name><name><surname>Jones</surname><given-names>T. M.</given-names></name><name><surname>Barbarash</surname><given-names>R. A.</given-names></name><name><surname>Mikolich</surname><given-names>D. J.</given-names></name><name><surname>Ruoff</surname><given-names>G. E.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial.</article-title>
<source><italic>J. Am. Acad. Dermatol.</italic></source>
<volume>45</volume>
<fpage>222</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1067/mjd.2001.116215</pub-id>
<?supplied-pmid 11464183?><pub-id pub-id-type="pmid">11464183</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoyo</surname><given-names>S.</given-names></name><name><surname>Jaime</surname><given-names>L.</given-names></name><name><surname>Plaza</surname><given-names>M.</given-names></name><name><surname>Herrero</surname><given-names>M.</given-names></name><name><surname>Rodriguez-Meizoso</surname><given-names>I.</given-names></name><name><surname>Ibanez</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Antiviral compounds obtained from microalgae commonly used as carotenoid sources.</article-title>
<source><italic>J. Appl. Phycol.</italic></source>
<volume>24</volume>
<fpage>731</fpage>&#x02013;<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1007/s10811-011-9692-1</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarisky</surname><given-names>R. T.</given-names></name><name><surname>Bacon</surname><given-names>T.</given-names></name><name><surname>Boon</surname><given-names>R.</given-names></name><name><surname>Locke</surname><given-names>L.</given-names></name><name><surname>Nguyen</surname><given-names>T. T.</given-names></name><name><surname>Leary</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>46</volume>
<fpage>2848</fpage>&#x02013;<lpage>2853</lpage>. <pub-id pub-id-type="doi">10.1128/aac.46.9.2848-2853.2002</pub-id>
<?supplied-pmid 12183237?><pub-id pub-id-type="pmid">12183237</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarisky</surname><given-names>R. T.</given-names></name><name><surname>Bacon</surname><given-names>T. H.</given-names></name><name><surname>Boon</surname><given-names>R. J.</given-names></name><name><surname>Duffy</surname><given-names>K. E.</given-names></name><name><surname>Esser</surname><given-names>K. M.</given-names></name><name><surname>Leary</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.</article-title>
<source><italic>Arch. Virol.</italic></source>
<volume>148</volume>
<fpage>1757</fpage>&#x02013;<lpage>1769</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-003-0124-7</pub-id>
<?supplied-pmid 14505088?><pub-id pub-id-type="pmid">14505088</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauerbrei</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Optimal management of genital herpes: current perspectives.</article-title>
<source><italic>Infect. Drug Resist.</italic></source>
<volume>9</volume>
<fpage>129</fpage>&#x02013;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S96164</pub-id>
<?supplied-pmid 27358569?><pub-id pub-id-type="pmid">27358569</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schillinger</surname><given-names>J. A.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Sternberg</surname><given-names>M. R.</given-names></name><name><surname>Armstrong</surname><given-names>G. L.</given-names></name><name><surname>Lee</surname><given-names>F. K.</given-names></name><name><surname>Nahmias</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994.</article-title>
<source><italic>Sex Transm. Dis.</italic></source>
<volume>31</volume>
<fpage>753</fpage>&#x02013;<lpage>760</lpage>. <pub-id pub-id-type="doi">10.1097/01.olq.0000145852.43262.c3</pub-id>
<?supplied-pmid 15608591?><pub-id pub-id-type="pmid">15608591</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>P.</given-names></name><name><surname>Sch&#x000f6;n</surname><given-names>K.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture.</article-title>
<source><italic>Pharmazie</italic></source>
<volume>56</volume>
<fpage>343</fpage>&#x02013;<lpage>347</lpage>. <?supplied-pmid 11338678?><pub-id pub-id-type="pmid">11338678</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>A. K.</given-names></name><name><surname>Harder</surname><given-names>B. C.</given-names></name><name><surname>Schlichtenbrede</surname><given-names>F. C.</given-names></name><name><surname>Jarczok</surname><given-names>M. N.</given-names></name><name><surname>Tesarz</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>1</volume>:<issue>CD011503</issue>.</mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebei</surname><given-names>K.</given-names></name><name><surname>Sakouhi</surname><given-names>F.</given-names></name><name><surname>Herchi</surname><given-names>W.</given-names></name><name><surname>Khouja</surname><given-names>M. L.</given-names></name><name><surname>Boukhchina</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Chemical composition and antibacterial activities of seven <italic>Eucalyptus</italic> species essential oils leaves.</article-title>
<source><italic>Biol. Res.</italic></source>
<volume>48</volume>
<fpage>1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25654588</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semprini</surname><given-names>A.</given-names></name><name><surname>Singer</surname><given-names>J.</given-names></name><name><surname>Braithwaite</surname><given-names>I.</given-names></name><name><surname>Shortt</surname><given-names>N.</given-names></name><name><surname>Thayabaran</surname><given-names>D.</given-names></name><name><surname>McConnell</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial.</article-title>
<source><italic>BMJ Open</italic></source>
<volume>9</volume>:<issue>e026201</issue>. <pub-id pub-id-type="doi">10.1136/bmjopen-2018-026201</pub-id>
<?supplied-pmid 31092654?><pub-id pub-id-type="pmid">31092654</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>B. T.</given-names></name><name><surname>Hatcher</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Complementary and alternative medicine in Pakistan: prospects and limitations.</article-title>
<source><italic>Evid. Based Compl. Altern. Med.</italic></source>
<volume>2</volume>
<fpage>139</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1093/ecam/neh088</pub-id>
<?supplied-pmid 15937553?><pub-id pub-id-type="pmid">15937553</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>D.</given-names></name><name><surname>Lyseng-Williamson</surname><given-names>K. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Famciclovir&#x02013; review of its use in herpes zoster and genital and orolabial herpes.</article-title>
<source><italic>Drugs</italic></source>
<volume>66</volume>
<fpage>2397</fpage>&#x02013;<lpage>2416</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200666180-00016</pub-id>
<?supplied-pmid 17181386?><pub-id pub-id-type="pmid">17181386</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>J.</given-names></name><name><surname>Verheyden</surname><given-names>J.</given-names></name><name><surname>Matthews</surname><given-names>T.</given-names></name></person-group> (<year>1983</year>). <article-title>Anti-Herpesvirus activity of the acyclic nucleoside 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>23</volume>
<fpage>676</fpage>&#x02013;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1128/aac.23.5.676</pub-id>
<?supplied-pmid 6307132?><pub-id pub-id-type="pmid">6307132</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J. S.</given-names></name><name><surname>Robinson</surname><given-names>N. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>186</volume>
<fpage>S3</fpage>&#x02013;<lpage>S28</lpage>. <?supplied-pmid 12353183?><pub-id pub-id-type="pmid">12353183</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soul-Lawton</surname><given-names>J.</given-names></name><name><surname>Seaber</surname><given-names>E.</given-names></name><name><surname>On</surname><given-names>N.</given-names></name><name><surname>Wootton</surname><given-names>R.</given-names></name><name><surname>Rolan</surname><given-names>P.</given-names></name><name><surname>Posner</surname><given-names>J.</given-names></name></person-group> (<year>1995</year>). <article-title>Absolute bioavailability and metabolic disposition of valaciclovir, the L- valyl ester of acyclovir, following oral administration to humans.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>39</volume>
<fpage>2759</fpage>&#x02013;<lpage>2764</lpage>. <pub-id pub-id-type="doi">10.1128/aac.39.12.2759</pub-id>
<?supplied-pmid 8593015?><pub-id pub-id-type="pmid">8593015</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>L. M.</given-names></name><name><surname>De Sassaki</surname><given-names>G. L.</given-names></name><name><surname>Teresa</surname><given-names>M.</given-names></name><name><surname>Romanos</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Structural characterization and Anti-HSV-1 and HSV-2 activity of glycolipids from the marine algae <italic>Osmundaria obtusiloba</italic> isolated from Southeastern Brazilian coast.</article-title>
<source><italic>Mar. Drugs.</italic></source>
<volume>10</volume>
<fpage>918</fpage>&#x02013;<lpage>931</lpage>. <pub-id pub-id-type="doi">10.3390/md10040918</pub-id>
<?supplied-pmid 22690151?><pub-id pub-id-type="pmid">22690151</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>T. M. L.</given-names></name><name><surname>Abrantes</surname><given-names>J. L.</given-names></name><name><surname>Epifanio</surname><given-names>R. D. A.</given-names></name><name><surname>Fontes</surname><given-names>C. F. L.</given-names></name><name><surname>Frugulhetti</surname><given-names>I. C. P. P.</given-names></name></person-group> (<year>2007</year>). <article-title>The alkaloid 4-methylaaptamine isolated from the sponge Aaptos aaptos impairs Herpes simplex virus type 1 penetration and immediate-early protein synthesis.</article-title>
<source><italic>Planta Med.</italic></source>
<volume>73</volume>
<fpage>200</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1055/s-2007-967109</pub-id>
<?supplied-pmid 17285480?><pub-id pub-id-type="pmid">17285480</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruance</surname><given-names>S. L.</given-names></name></person-group> (<year>1993</year>). <article-title>Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis.</article-title>
<source><italic>J. Med. Virol.</italic></source>
<volume>41</volume>(<issue>1 Suppl</issue>), <fpage>27</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.1890410507</pub-id>
<?supplied-pmid 8245889?><pub-id pub-id-type="pmid">8245889</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruance</surname><given-names>S. L.</given-names></name><name><surname>Overall</surname><given-names>J. C.</given-names><suffix>Jr.</suffix></name><name><surname>Kern</surname><given-names>E. R.</given-names></name><name><surname>Krueger</surname><given-names>G. G.</given-names></name><name><surname>Pliam</surname><given-names>V.</given-names></name><etal/></person-group> (<year>1977</year>). <article-title>The natural history of recurrent herpes simplex labialis: implications for antiviral therapy.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>297</volume>
<fpage>69</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1056/nejm197707142970201</pub-id>
<?supplied-pmid 194157?><pub-id pub-id-type="pmid">194157</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruance</surname><given-names>S. L.</given-names></name><name><surname>Stewart</surname><given-names>J. C.</given-names></name><name><surname>Rowe</surname><given-names>N. H.</given-names></name><name><surname>McKeough</surname><given-names>M. B.</given-names></name><name><surname>Wenerstrom</surname><given-names>G.</given-names></name><name><surname>Freeman</surname><given-names>D. J.</given-names></name></person-group> (<year>1990</year>). <article-title>Treatment of recurrent herpes simplex labialis with oral acyclovir.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>161</volume>
<fpage>185</fpage>&#x02013;<lpage>190</lpage>. <?supplied-pmid 2153735?><pub-id pub-id-type="pmid">2153735</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>J. G.</given-names></name><name><surname>Cook</surname><given-names>M. L.</given-names></name></person-group> (<year>1971</year>). <article-title>Latent herpes simplex virus in spinal ganglia of mice.</article-title>
<source><italic>Science</italic></source>
<volume>173</volume>
<fpage>843</fpage>&#x02013;<lpage>845</lpage>. <pub-id pub-id-type="doi">10.1126/science.173.3999.843</pub-id>
<?supplied-pmid 4328483?><pub-id pub-id-type="pmid">4328483</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>A.</given-names></name><name><surname>B&#x000f6;ttiger</surname><given-names>D.</given-names></name><name><surname>Gever</surname><given-names>L. N.</given-names></name><name><surname>Wheeler</surname><given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>Safety and tolerability of combination acyclovir 5% and hydrocortisone 1% cream in adolescents with recurrent herpes simplex labialis.</article-title>
<source><italic>Pediatr. Dermatol.</italic></source>
<volume>29</volume>
<fpage>105</fpage>&#x02013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1111/j.1525-1470.2011.01570.x</pub-id>
<?supplied-pmid 22004219?><pub-id pub-id-type="pmid">22004219</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stranska</surname><given-names>R.</given-names></name><name><surname>Schuurman</surname><given-names>R.</given-names></name><name><surname>Nienhuis</surname><given-names>E.</given-names></name><name><surname>Goedegebuure</surname><given-names>I. W.</given-names></name><name><surname>Polman</surname><given-names>M.</given-names></name><name><surname>Weel</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.</article-title>
<source><italic>J. Clin. Virol.</italic></source>
<volume>32</volume>
<fpage>7</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2004.04.002</pub-id>
<?supplied-pmid 15572000?><pub-id pub-id-type="pmid">15572000</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suazo</surname><given-names>P. A.</given-names></name><name><surname>Tognarelli</surname><given-names>E. I.</given-names></name><name><surname>Kalergis</surname><given-names>A. M.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>P. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.</article-title>
<source><italic>Med. Microbiol. Immunol.</italic></source>
<volume>204</volume>
<fpage>161</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1007/s00430-014-0358-x</pub-id>
<?supplied-pmid 25209142?><pub-id pub-id-type="pmid">25209142</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q. L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>L. Q.</given-names></name><name><surname>Li</surname><given-names>Y. X.</given-names></name><name><surname>Cui</surname><given-names>Y. S.</given-names></name><name><surname>Jiang</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Structural characterization and antiviral activity of two fucoidans from the brown algae <italic>Sargassum henslowianum</italic>.</article-title>
<source><italic>Carbohydr. Polym.</italic></source>
<volume>229</volume>:<issue>115487</issue>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2019</pub-id>
<?supplied-pmid 31826428?><pub-id pub-id-type="pmid">31826428</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachjian</surname><given-names>A.</given-names></name><name><surname>Maria</surname><given-names>V.</given-names></name><name><surname>Jahangir</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Use of Herbal Products and Potential Interactions in Patients With Cardiovascular Diseases.</article-title>
<source><italic>J. Am. Coll. Cardiol.</italic></source>
<volume>55</volume>
<fpage>515</fpage>&#x02013;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2009.07.074</pub-id>
<?supplied-pmid 20152556?><pub-id pub-id-type="pmid">20152556</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor-Robinson</surname><given-names>D.</given-names></name><name><surname>Ballard</surname><given-names>R. C.</given-names></name></person-group> (<year>2001</year>). <article-title>In vitro inactivation of Chlamydia trachomatis and of a panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the spermicide benzalkonium chloride.</article-title>
<source><italic>J. Antimicrob. Chemother.</italic></source>
<volume>46</volume>
<fpage>685</fpage>&#x02013;<lpage>693</lpage>. <pub-id pub-id-type="doi">10.1093/jac/46.5.685</pub-id>
<?supplied-pmid 11062186?><pub-id pub-id-type="pmid">11062186</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thin</surname><given-names>R. N.</given-names></name><name><surname>Nabarro</surname><given-names>J. M.</given-names></name><name><surname>Parker</surname><given-names>J. D.</given-names></name><name><surname>Fiddian</surname><given-names>A. P.</given-names></name></person-group> (<year>1983</year>). <article-title>Topical acyclovir in the treatment of initial genital herpes.</article-title>
<source><italic>Sex Transm. Infect.</italic></source>
<volume>59</volume>
<fpage>116</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1136/sti.59.2.116</pub-id>
<?supplied-pmid 6338997?><pub-id pub-id-type="pmid">6338997</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomford</surname><given-names>N. E.</given-names></name><name><surname>Senthebane</surname><given-names>D. A.</given-names></name><name><surname>Rowe</surname><given-names>A.</given-names></name><name><surname>Munro</surname><given-names>D.</given-names></name><name><surname>Seele</surname><given-names>P.</given-names></name><name><surname>Maroyi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Natural products for drug discovery in the 21st century: innovations for novel drug discovery.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>19</volume>:<issue>E1578</issue>. <pub-id pub-id-type="doi">10.3390/ijms19061578</pub-id>
<?supplied-pmid 29799486?><pub-id pub-id-type="pmid">29799486</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuy</surname><given-names>T. T.</given-names></name><name><surname>Ly</surname><given-names>B. M.</given-names></name><name><surname>Van</surname><given-names>T. T.</given-names></name><name><surname>Quang</surname><given-names>N. V.</given-names></name><name><surname>Tu</surname><given-names>H. C.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Anti-HIV activity of fucoidans from three brown seaweed species.</article-title>
<source><italic>Carbohydr. Polym.</italic></source>
<volume>115</volume>
<fpage>122</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2014.08.068</pub-id>
<?supplied-pmid 25439876?><pub-id pub-id-type="pmid">25439876</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treister</surname><given-names>N. S.</given-names></name><name><surname>Woo</surname><given-names>S. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Topical n-docosanol for management of recurrent herpes labialis.</article-title>
<source><italic>Expert Opin. Pharmacother.</italic></source>
<volume>11</volume>
<fpage>853</fpage>&#x02013;<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1517/14656561003691847</pub-id>
<?supplied-pmid 20210688?><pub-id pub-id-type="pmid">20210688</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Diemen</surname><given-names>F. R.</given-names></name><name><surname>Kruse</surname><given-names>E. M.</given-names></name><name><surname>Hooykaas</surname><given-names>M. J. G.</given-names></name><name><surname>Bruggeling</surname><given-names>C. E.</given-names></name><name><surname>Sch&#x000fc;rch</surname><given-names>A. C.</given-names></name><name><surname>van Ham</surname><given-names>P. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>12</volume>:<issue>e1005701</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005701</pub-id>
<?supplied-pmid 27362483?><pub-id pub-id-type="pmid">27362483</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Diemen</surname><given-names>F. R.</given-names></name><name><surname>Lebbink</surname><given-names>R. J.</given-names></name></person-group> (<year>2017</year>). <article-title>CRISPR/Cas9, a powerful tool to target human herpesviruses.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>19</volume>
<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/cmi.12694</pub-id>
<?supplied-pmid 27860066?><pub-id pub-id-type="pmid">27860066</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturi</surname><given-names>C. R.</given-names></name><name><surname>Danielli</surname><given-names>L. J.</given-names></name><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Apel</surname><given-names>M. A.</given-names></name><name><surname>Montanha</surname><given-names>J. A.</given-names></name><name><surname>Bordignon</surname><given-names>S. A. L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Chemical analysis and in vitro antiviral and antifungal activities of essential oils from <italic>Glechon spathulata</italic> and <italic>Glechon marifolia</italic>.</article-title>
<source><italic>Pharm. Biol.</italic></source>
<volume>53</volume>
<fpage>682</fpage>&#x02013;<lpage>688</lpage>. <pub-id pub-id-type="doi">10.3109/13880209.2014.936944</pub-id>
<?supplied-pmid 25431185?><pub-id pub-id-type="pmid">25431185</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vere Hodge</surname><given-names>R. A.</given-names></name><name><surname>Field</surname><given-names>H. J.</given-names></name></person-group> (<year>2013</year>). &#x0201c;<article-title>Antiviral agents for herpes simplex virus</article-title>,&#x0201d; in <source><italic>Advances in Pharmacology</italic></source>, <edition>1st Edn</edition>, <volume>Vol. 67</volume>
<role>eds</role>
<person-group person-group-type="editor"><name><surname>August</surname><given-names>J. T.</given-names></name><name><surname>Anders</surname><given-names>M. W.</given-names></name><name><surname>Murad</surname><given-names>F.</given-names></name><name><surname>Coye</surname><given-names>J. T.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Inc</publisher-name>), <fpage>1</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-405880-4.00001-9</pub-id>
<?supplied-pmid 23885997?></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagstaff</surname><given-names>A. J.</given-names></name><name><surname>Bryson</surname><given-names>H. M.</given-names></name></person-group> (<year>1994</year>). <article-title>Foscarnet - a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral-infections.</article-title>
<source><italic>Drugs</italic></source>
<volume>48</volume>
<fpage>199</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-199448020-00007</pub-id>
<?supplied-pmid 7527325?><pub-id pub-id-type="pmid">7527325</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>A.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Timmler</surname><given-names>B.</given-names></name><name><surname>Magaret</surname><given-names>A.</given-names></name><name><surname>Warren</surname><given-names>T.</given-names></name><name><surname>Tyring</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Helicase&#x02013;primase inhibitor pritelivir for HSV-2 infection.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>370</volume>
<fpage>201</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1301150</pub-id>
<?supplied-pmid 24428466?><pub-id pub-id-type="pmid">24428466</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitley</surname><given-names>R.</given-names></name><name><surname>Davis</surname><given-names>E. A.</given-names></name><name><surname>Suppapanya</surname><given-names>N.</given-names></name></person-group> (<year>2007</year>). <article-title>Incidence of neonatal herpes simplex virus infections in a managed-care population.</article-title>
<source><italic>Sex Transm. Dis.</italic></source>
<volume>34</volume>
<fpage>704</fpage>&#x02013;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1097/01.olq.0000258432.33412.e2</pub-id>
<?supplied-pmid 17413535?><pub-id pub-id-type="pmid">17413535</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="book"><collab>WHO</collab> (<year>2000</year>). <source><italic>General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization.</italic></source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Heal Organisation</publisher-name>.</mixed-citation></ref><ref id="B199"><mixed-citation publication-type="book"><collab>WHO</collab> (<year>2004</year>). <source><italic>WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems.</italic></source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organisation</publisher-name>, <fpage>82</fpage>.</mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelmus</surname><given-names>K. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>2015</volume>
<fpage>1</fpage>&#x02013;<lpage>231</lpage>.</mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>K. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use final rule.</article-title>
<source><italic>Fed. Regist.</italic></source>
<volume>82</volume>
<fpage>60474</fpage>&#x02013;<lpage>60503</lpage>. <?supplied-pmid 29260839?><pub-id pub-id-type="pmid">29260839</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>S. B.</given-names></name><name><surname>Challacombe</surname><given-names>S. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Management of recurrent oral herpes simplex infections.</article-title>
<source><italic>Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod.</italic></source>
<volume>103</volume>(<issue>Suppl. 12</issue>), <fpage>e1</fpage>&#x02013;<lpage>e18</lpage>.</mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyles</surname><given-names>D. L.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Madinger</surname><given-names>N.</given-names></name><name><surname>Bessesen</surname><given-names>M.</given-names></name><name><surname>Krause</surname><given-names>P. R.</given-names></name><name><surname>Weinberg</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Development of herpes simplex virus disease in patients who are receiving cidofovir.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>41</volume>
<fpage>676</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1086/432477</pub-id>
<?supplied-pmid 16080090?><pub-id pub-id-type="pmid">16080090</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Markowitz</surname><given-names>L. E.</given-names></name><name><surname>Gottlieb</surname><given-names>S. L.</given-names></name><name><surname>Berman</surname><given-names>S. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States.</article-title>
<source><italic>Am. J. Obs. Gynecol.</italic></source>
<volume>196</volume>
<fpage>e1</fpage>&#x02013;<lpage>e6</lpage>.</mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Piao</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>The traditional medicine and modern medicine from natural products.</article-title>
<source><italic>Molecules</italic></source>
<volume>21</volume>:<issue>E559</issue>. <pub-id pub-id-type="doi">10.3390/molecules21050559</pub-id>
<?supplied-pmid 27136524?><pub-id pub-id-type="pmid">27136524</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname><given-names>K.</given-names></name><name><surname>Fouladvand</surname><given-names>M.</given-names></name><name><surname>Pakdel</surname><given-names>P.</given-names></name><name><surname>Sartavi</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Evaluation of in vitro antiviral activity of a brown alga (<italic>Cystoseira myrica</italic>) from the Persian Gulf against herpes simplex virus type 1.</article-title>
<source><italic>Afr. J. Biotechnol.</italic></source>
<volume>6</volume>
<fpage>2511</fpage>&#x02013;<lpage>2514</lpage>. <pub-id pub-id-type="doi">10.5897/ajb2007.000-2399</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziyaeyan</surname><given-names>M.</given-names></name><name><surname>Alborzi</surname><given-names>A.</given-names></name><name><surname>Japoni</surname><given-names>A.</given-names></name><name><surname>Kadivar</surname><given-names>M.</given-names></name><name><surname>Davarpanah</surname><given-names>M. A.</given-names></name><name><surname>Pourabbas</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.</article-title>
<source><italic>Int. J. Dermatol.</italic></source>
<volume>46</volume>
<fpage>1263</fpage>&#x02013;<lpage>1266</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-4632.2007.03449.x</pub-id>
<?supplied-pmid 18173520?><pub-id pub-id-type="pmid">18173520</pub-id></mixed-citation></ref></ref-list></back></article>